

10/18/00  
1054 US PTO

Please type a plus sign (+) inside this box →

PTO/SB/05 (4/98)

Approved for use through 09/30/2000. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53 (b))

Attorney Docket No.	LEX-0070-USA
First Inventor or Application Identifier	C. Alexander Turner Jr. et al.
Title	Novel Human Proteins and Polynucleotides Encoding the Same
Express Mail label No.	EL672756158US

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

1  \*Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)

2  Specification [Total 54 Pages]  
(preferred arrangement set forth below)

- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the disclosure

3  Drawing(s)(35 U.S.C.113) [Total 1 Sheets]

4 Oath or Declaration [Total 1 ]

a.  Newly unexecuted (original or copy)

b.  Copy from a prior application (37 C.F.R. § 1.63(d))  
(for continuation/divisional with Box 16 completed)

i.  DELETION OF INVENTOR(S)  
Signed statement attached deleting  
inventor(s) named in the prior application,  
see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

*\*NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES,  
SMALL ENTITY STATEMENT IS REQUIRED (37 CFR. § 127), EXCEPT IF  
ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 CFR. §128).*

ADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

5  Microfiche Computer Program (Appendix)

6. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
 

- a.  Computer Readable Copy
- b.  Paper Copy (identical to computer copy)
- c.  Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

7.  Assignment Papers (cover sheet & document(s))

8.  37 C.F.R. §3.73(b) Statement  
(when there is an assignee)  Power of Attorney

9.  English Translation Document (if applicable)

10.  Information Disclosure Statement (IDS)/PTO-1449  Copies of IDS Citations

11.  Preliminary Amendment

12.  Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)

13.  \*Small Entity Statement(s)  Statement filed in prior application,  
(PTO/B/09-12) Status still proper and desired

14.  Certified Copy of Priority Document(s)  
(if foreign priority is claimed)

15. Other: .....

16. If a CONTINUATING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

Continuation  Divisional  Continuation-in-part (CIP) of prior application No: \_\_\_\_\_

Prior application information: Examiner \_\_\_\_\_

Group/Art Unit: \_\_\_\_\_

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.

## 17. CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number or Bar Code Label		or <input type="checkbox"/> Correspondence address below
Name	24231	
Address	PATENT TRADEMARK OFFICE	
City	State	Zip Code
Country	Telephone (281) 362-6554	Fax (281) 364-0155

Name (Print/Type)	Lance K. Ishimoto	Registration No.	41866
Signature	Lance K. Ishimoto	Date	October 18, 2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

**STATEMENT CLAIMING SMALL ENTITY STATUS  
(37 CFR 1.9(f) & 1.27(c)) -- SMALL BUSINESS CONCERN**

Docket Number (Optional)  
**LEX-0070-USA**



Applicant, Patentee, or Identifier: C. Alexander Turner Jr. et al.

Application or Patent No.:

Filed or Issued: October 18, 2000

Title: Novel Human Proteins and Polynucleotides Encoding the Same

I hereby state that I am

the owner of the small business concern identified below:  
 an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN Lexicon Genetics Incorporated

ADDRESS OF SMALL BUSINESS CONCERN 4000 Research Forest Drive, The Woodlands, TX 77381

I hereby state that the above identified small business concern qualifies as a small business concern as defined in 13 CFR Part 121 for purposes of paying reduced fees to the United States Patent and Trademark Office. Questions related to size standards for a small business concern may be directed to: Small Business Administration, Size Standards Staff, 409 Third Street, SW, Washington, DC 20416.

I hereby state that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in:

the specification filed herewith with title as listed above.  
 the application identified above.  
 the patent identified above.

If the rights held by the above identified small business concern are not exclusive, each individual, concern, or organization having rights in the invention must file separate statements as to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

Each person concern, or organization having any rights in the invention is listed below:

No such persons, concerns, or organizations exist.  
 each such person, concerns, or organization is listed below:

Separate statements are required from each named person, concern, or organization having rights to the invention stating their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

NAME OF PERSON SIGNING Lance K. Ishimoto

TITLE OF PERSON IF OTHER THAN OWNER Vice President - Intellectual Property

ADDRESS OF PERSON SIGNING 4000 Research Forest Drive, The Woodlands, TX 77381

SIGNATURE \_\_\_\_\_  
Reg. No. 41,866

DATE October 18, 2000

JC917 U.S. PTO  
09/691743  
10/18/00

NOVEL HUMAN PROTEINS AND  
POLYNUCLEOTIDES ENCODING THE SAME

1. INTRODUCTION

The present application claims the benefit of U.S. 5 Provisional Application Serial Nos: 60/160,106 and 60/162,547 which were filed on October 18, 1999 and October 29, 1999, respectively, and are herein incorporated by reference in their entirety.

The present invention relates to the discovery, 10 identification, and characterization of novel human polynucleotides that encode proteins, and, more particularly, secreted proteins. The invention encompasses the described 15 polynucleotides, host cell expression systems, the encoded proteins, fusion proteins, polypeptides and peptides, antibodies to the encoded proteins and peptides, and genetically engineered 20 animals that lack the disclosed sequences, or over express the disclosed sequences, or antagonists and agonists of the proteins, and other compounds that modulate the expression or activity of the proteins encoded by the disclosed sequences that can be used for diagnosis, drug screening, clinical trial monitoring, the treatment of physiological or behavioral disorders, cancer, and 25 infectious disease.

2. BACKGROUND OF THE INVENTION

Proteins are integral components of the various systems used 25 by the body to monitor and regulate different bodily functions. In particular, secreted proteins, or circulating fragments or portions of other proteins, are often involved in regulating and maintaining a wide variety of biological and physiological processes. Often, such processes are mediated by protein ligands 30 that interact with corresponding membrane receptor proteins that activate signal transduction and other pathways that control cell physiology, chemical release and communication, and gene expression. As such, ligand/receptor interactions constitute

ideal targets for drug intervention and for the design of therapeutic agents.

### **3. SUMMARY OF THE INVENTION**

The present invention relates to the discovery, 5 identification, and characterization of nucleotides that encode novel human proteins, polypeptides, and peptides, and the corresponding amino acid sequences thereof.

The novel human proteins (NHPs) described for the first time herein share structural motifs typical of human secreted proteins.

10 Two of the novel human nucleic acid sequences described herein, encode proteins/open reading frames (ORFs) of 451 and 429 amino acids in length (see SEQ ID NOS: 2 and 4 respectively). These novel human proteins (NHPs) described for the first time herein share structural similarity with animal chordins, NEL protein, and 15 thrombospondin. Chordins are developmentally active proteins that are antagonists of bone morphogenic protein (BMP) 4, and serve as targets for proteolytic cleavage by BMP-1. Chordin has been implicated in developmental regulation during gastrulation and skeletogenesis. The regions of the described proteins that 20 constitute the chordin-like domains also display marked similarity with human NEL protein and animal thrombospondins. In addition to development, these proteins have been associated with biological 25 activities such as, for example, the inhibition of angiogenesis, clotting, and adrenal secretion.

25 The other novel human nucleic acid sequence (SEQ ID NO: 6) described herein, encodes an ORF of 305 amino acids in length (see SEQ ID NO: 7). This NHP, described for the first time herein, shares structural similarity with animal proteins that contain CUB domains. The CUB domain is an extracellular domain (ECD) present 30 in variety of diverse proteins such as bone morphogenetic protein 1, proteinases, spermidhesins, complement subcomponents, and neuronal recognition molecules. The described NHP also displays significant similarity with bone morphogenic protein, neuropilin and vascular endothelial growth factor. As such, this novel 35 sequence represents a new member of the platelet-derived growth

factor/VEGF family of proteins, which have a range of homologues and orthologs that transcend phyla and species.

The invention encompasses the nucleotides presented in the Sequence Listing, host cells expressing such nucleotides, the 5 expression products of such nucleotides, and: (a) nucleotides that encode mammalian homologs of the described sequences, including the specifically described NHPs, and the NHP products; (b) nucleotides that encode one or more portions of the NHPs that correspond to functional domains, and the polypeptide products 10 specified by such nucleotide sequences, including but not limited to the novel regions of any active domain(s); (c) isolated nucleotides that encode mutant versions, engineered or naturally occurring, of the described NHPs in which all or a part of at least one domain is deleted or altered, and the polypeptide 15 products specified by such nucleotide sequences, including but not limited to soluble proteins and peptides in which all or a portion of the signal sequence is deleted; and (d) nucleotides that encode chimeric fusion proteins containing all or a portion of a coding 20 region of an NHP, or one of its domains (e.g., a receptor binding domain, accessory protein/self-association domain, etc.) fused to another peptide or polypeptide.

The invention also encompasses agonists and antagonists of the NHPs, including small molecules, large molecules, mutant NHPs, or portions thereof that compete with native NHP, and antibodies, 25 as well as nucleotide sequences that can be used to inhibit the expression of the described NHPs (e.g., antisense and ribozyme molecules, and gene or regulatory sequence replacement constructs) or to enhance the expression of the described NHP sequences (e.g., expression constructs that place the described sequence under the 30 control of a strong promoter system), and transgenic animals that express a NHP transgene. Additionally, "knock-out" animals are contemplated (which can be conditional) that have been engineered such that they do not express a functional NHP gene (see, for example, PCT Applic. No. PCT/US98/03243, filed February 20, 1998, 35 herein incorporated by reference). Another aspect of the present invention includes cells and animals that have specifically

engineered mutations (point mutations, over expression of an NHP gene, etc.) the genes encoding the presently described NHPs.

Further, the present invention also relates to methods of using the described NHPs and/or NHP products for the

5 identification of compounds that modulate, *i.e.*, act as agonists or antagonists, of NHP expression and/or NHP product activity.

Like the described NHPs, such compounds can be used as therapeutic agents for the treatment of any of a wide variety of symptomatic representations of biological disorders or imbalances.

10

#### **4. DESCRIPTION OF THE SEQUENCE LISTING AND FIGURES**

The Sequence Listing provides the sequence of four nucleotide sequences and the novel amino acid sequences encoded by three of 15 them. SEQ ID NO:5 describes a NHP ORF and flanking sequences.

#### **5. DETAILED DESCRIPTION OF THE INVENTION**

The NHPs, described for the first time herein, are novel 20 proteins that are expressed in, *inter alia*, human cell lines, gene trapped human cell lines and cervix cells. When secreted, the NHPs typically exert physiological effect by interacting with receptors to produce a biological effect (such as, for example, signal transduction). Consequently, interfering with the binding 25 of a NHP product to its cognate receptor effects NHP-mediated processes. Alternatively, enhancing the concentration of a NHP product *in vivo*, can boost the effects/activity levels of such NHP affected processes. Yet another alternative is that the described NHPs, or portions thereof, can act as hormones (or peptide 30 hormones), enzymes, or receptor/ligand antagonists and used accordingly.

Because secreted proteins are considered to be more likely to effect some biological activity, the genes encoding such proteins (and the proteins encoded thereby as well as the uses and 35 formulations thereof) have been the subjects of intense scientific/commercial scrutiny (see, for example, Applic. Ser. Nos. PCT/US98/04858 (from 60/068,368, 60/057,765, 60/048,970, 60/040,762 and others listed on the face of the application) filed March 12, 1998, 09/040,963, filed March 18, 1998, PCT/US98/05255

(corresponding to 60/041,263), filed March 18, 1998, all of which are herein incorporated by reference in their entirety). The presently described NHPs have structural motifs consistent with other human secreted proteins.

5 The invention encompasses the use of the described NHP nucleotides, NHPs, and peptides, as well as antibodies, preferably humanized monoclonal antibodies, or binding fragments, domains, or fusion proteins thereof, or antiidotypic variants derived therefrom, that bind NHPs (which can, for example, also act as NHP  
10 agonists or antagonists), other antagonists that inhibit binding activity or expression, or agonists that activate NHP receptor activity or increase NHP expression, in the diagnosis and/or treatment of disease.

In particular, the invention described in the subsections  
15 below encompasses the described NHPs, or peptides corresponding to functional domains of NHPs, mutated NHPs, truncated NHPs, mature cleavage products of NHPs (which may occur, prior to, during, or subsequent to secretion), or deleted NHPs (e.g., NHPs missing one or more functional regions, domains, or portions thereof), NHP  
20 fusion proteins (e.g., a NHP or a functional domain of a NHP fused to an unrelated protein or peptide such as an immunoglobulin constant region, *i.e.*, IgFc), nucleotide sequences encoding such products, and host cell expression systems that can produce such NHP products.

25 The invention also encompasses antibodies and anti-idiotypic antibodies (including Fab fragments), antagonists and agonists of the NHP, as well as compounds or nucleotide constructs that inhibit expression of a NHP gene (transcription factor inhibitors, antisense and ribozyme molecules, or gene or regulatory sequence  
30 replacement constructs), or promote expression of NHPs (e.g., expression constructs in which NHP coding sequences are operatively associated with expression control elements such as promoters, promoter/enancers, etc.). The invention also relates to host cells and animals genetically engineered to express the  
35 NHPs (or mutant variants thereof) or to inhibit, or "knock-out", expression of an animal homolog of an endogenous NHP gene.

As putative secreted proteins/peptides, signal peptides associated with the described amino acid sequences may be typically cleaved during secretion of the mature protein products. Analysis of the described proteins/peptides reveals the presence 5 of predicted signal cleavage sites between about 13 and about 53 amino acids into the described proteins (from the initiation methionine). Computer predictions of signal peptidase cleavage sites being less than absolutely accurate, an additional aspect of the present invention includes any and all mature cleavage 10 products remaining after removal of between about the first 10 and about the first 55 amino acids, or any number in-between (as applicable given the length of the described protein), that leaves (for secretion) at least about 3, and preferably at least about 6 to 20, or more, amino acids of the protein product originally 15 encoded by the described NHP sequences (for secretion).

The NHPs or peptides, NHP fusion proteins, NHP nucleotide sequences, antibodies, antagonists and agonists can be useful for the detection of mutant NHPs or inappropriately expressed NHPs for the diagnosis of disease. The NHP proteins or peptides, NHP 20 fusion proteins, NHP nucleotide sequences, host cell expression systems, antibodies, antagonists, agonists and genetically engineered cells and animals can be used for screening for drugs (or high throughput screening of combinatorial libraries) 25 effective in the treatment of the symptomatic or phenotypic manifestations of perturbing the normal function of NHP in the body. The use of engineered host cells and/or animals may offer an advantage in that such systems allow not only for the identification of compounds that bind to the endogenous receptor for an NHP, but can also identify compounds that trigger NHP- 30 mediated signal transduction.

Finally, the NHP products (especially soluble derivatives such as peptides corresponding to the, and fusion protein products (especially NHP-Ig fusion proteins, *i.e.*, fusions of a NHP, or a domain of a NHP, to an IgFc), antibodies and anti-idiotypic 35 antibodies (including Fab fragments), antagonists or agonists (including compounds that modulate signal transduction which may act on downstream targets in a NHP-mediated signal transduction

pathway) can be used to directly treat diseases or disorders. For example, the administration of an effective amount of soluble NHP, or a NHP-IgFc fusion protein or an anti-idiotypic antibody (or its Fab) that mimics the NHP could activate or neutralize the  
5 endogenous NHP receptor. Nucleotide constructs encoding such NHP products can be used to genetically engineer host cells to express such products *in vivo*; these genetically engineered cells function as "bioreactors" in the body delivering a continuous supply of a NHP, a NHP peptide, or a NHP fusion protein to the body.  
10 Nucleotide constructs encoding functional NHPs, mutant NHPs, as well as antisense and ribozyme molecules can also be used in "gene therapy" approaches for the modulation of NHP expression. Thus, the invention also encompasses pharmaceutical formulations and methods for treating biological disorders, boosting immune  
15 function, or combating infectious agents.

Various aspects of the invention are described in greater detail in the subsections below.

### **5.1 THE NHP SEQUENCES**

20 The cDNA sequences (SEQ ID NOS: 1, 3 and 6) and the corresponding deduced amino acid sequences (SEQ ID NOS: 2, 4 and 7) of the described NHPs are presented in the Sequence Listing.  
25 The two NHP nucleotides described in SEQ ID NOS: 1 and 3 were obtained from human gene trapped sequence tags and polynucleotide isolated from a human adrenal gland library (Edge Biosystems, Gaithersburg, MD). SEQ ID NO:5 shows a polynucleotide sequence encoding a NHP ORF as well as 5' and 3' flanking regions.

30 The NHP nucleotides described in SEQ ID NO:6 were obtained from clustered human gene trapped sequences and ESTs. In addition to the genes encoding PDGF and VEGF family proteins, the NHPs described in SEQ ID NO:7 shares significant similarity to a variety of CUB domain proteins such as bone morphogenetic protein, C-proteinases and endopeptidases, neuropilin, human NP-2, 35 semaphorin, sperm adhesins, bovine acidic seminal fluid protein, and other secretory proteins. The described open reading frames can also contain a polymorphism including an A to G transition at

base 598 of SEQ ID NO:6 which converts the isoleucine at position 200 of SEQ ID NO:7 to a valine.

The NHPs of the present invention include: (a) the human DNA sequences presented in the Sequence Listing, and additionally 5 contemplate any nucleotide sequence encoding a contiguous and functional NHP open reading frame (ORF) that hybridizes to a complement of the DNA sequences presented in the Sequence Listing under highly stringent conditions, *e.g.*, hybridization to filter-bound DNA in 0.5 M NaHPO<sub>4</sub>, 7% sodium dodecyl sulfate (SDS), 1 mM 10 EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C (Ausubel F.M. *et al.*, eds., 1989, *Current Protocols in Molecular Biology*, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at p. 2.10.3) and encodes a functionally 15 equivalent gene product. Additionally contemplated are any nucleotide sequences that hybridize to the complement of the DNA sequences that encode and express an amino acid sequence presented in the Sequence Listing under moderately stringent conditions, 20 *e.g.*, washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel *et al.*, 1989, *supra*), yet which still encode a functionally equivalent NHP product. Functional equivalents of NHPs include naturally occurring NHPs present in other species, and mutant NHPs whether naturally occurring or engineered. The invention also includes 25 degenerate variants of the disclosed sequences.

The invention also includes nucleic acid molecules, 25 preferably DNA molecules, that hybridize to, and are therefore the complements of, the described NHP nucleotide sequences. Such hybridization conditions may be highly stringent or less highly stringent, as described above. In instances wherein the nucleic acid molecules are deoxyoligonucleotides ("DNA oligos"), such 30 molecules (and particularly about 16 to about 100 base long, about 20 to about 80, or about 34 to about 45 base long, or any variation or combination of sizes represented therein incorporating a contiguous region of sequence first disclosed in the Sequence Listing, can be used in conjunction with the 35 polymerase chain reaction (PCR) to screen libraries, isolate clones, and prepare cloning and sequencing templates, etc.

Alternatively, the oligonucleotides can be used as hybridization probes. For oligonucleotide probes, highly stringent conditions may refer, e.g., to washing in 6xSSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligos), 48°C (for 17-base oligos), 55°C (for 20-base oligos), and 60°C (for 23-base oligos). These nucleic acid molecules may encode or act as NHP gene antisense molecules, useful, for example, in NHP gene regulation (for and/or as antisense primers in amplification reactions of NHP gene nucleic acid sequences). With respect to NHP gene regulation, such techniques can be used to regulate biological functions. Further, such sequences may be used as part of ribozyme and/or triple helix sequences, also useful for NHP gene regulation.

Additionally, the antisense oligonucleotides may comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from

the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

5 In yet another embodiment, the antisense oligonucleotide is an  $\alpha$ -anomeric oligonucleotide. An  $\alpha$ -anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual  $\beta$ -units, the strands run parallel to each other (Gautier et al., 1987, Nucl. Acids Res. 15:6625-6641).

10 The oligonucleotide is a 2'-0-methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, FEBS Lett. 215:327-330).

Oligonucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

Low stringency conditions are well known to those of skill in the art, and will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived. For guidance regarding such conditions see, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual (and periodic updates thereof), Cold Springs Harbor Press, N.Y.; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y.

30 Alternatively, suitably labeled NHP nucleotide probes may be used to screen a human genomic library using appropriately stringent conditions or by PCR. The identification and characterization of human genomic clones is helpful for identifying polymorphisms, determining the genomic structure of a given locus/allele, and designing diagnostic tests. For example, sequences derived from regions adjacent to the intron/exon boundaries of the human gene can be used to design primers for use

in amplification assays to detect mutations within the exons, introns, splice sites (e.g., splice acceptor and/or donor sites), etc., that can be used in diagnostics and pharmacogenomics.

Further, a NHP gene homolog may be isolated from nucleic acid 5 of the organism of interest by performing PCR using two degenerate oligonucleotide primer pools designed on the basis of amino acid sequences within the NHP product disclosed herein. The template for the reaction may be total RNA, mRNA, and/or cDNA obtained by reverse transcription of mRNA prepared from, for example, human or 10 non-human cell lines or tissue, such as choroid plexus, known or suspected to express a NHP gene allele.

The PCR product may be subcloned and sequenced to ensure that the amplified sequences represent the sequence of the desired NHP gene. The PCR fragment may then be used to isolate a full length 05 cDNA clone by a variety of methods. For example, the amplified fragment may be labeled and used to screen a cDNA library, such as a bacteriophage cDNA library. Alternatively, the labeled fragment may be used to isolate genomic clones via the screening of a genomic library.

PCR technology may also be utilized to isolate full length 20 cDNA sequences. For example, RNA may be isolated, following standard procedures, from an appropriate cellular or tissue source (i.e., one known, or suspected, to express a NHP gene, such as, for example, brain tissue). A reverse transcription (RT) reaction 25 may be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis. The resulting RNA/DNA hybrid may then be "tailed" using a standard terminal transferase reaction, the hybrid may be digested with RNase H, and second 30 strand synthesis may then be primed with a complementary primer. Thus, cDNA sequences upstream of the amplified fragment may easily be isolated. For a review of cloning strategies which may be used, see e.g., Sambrook *et al.*, 1989, *supra*.

A cDNA of a mutant NHP gene may be isolated, for example, by 35 using PCR. In this case, the first cDNA strand may be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from tissue known or suspected to be expressed in an individual

putatively carrying a mutant NHP allele, and by extending the new strand with reverse transcriptase. The second strand of the cDNA is then synthesized using an oligonucleotide that hybridizes specifically to the 5' end of the normal gene. Using these two 5 primers, the product is then amplified via PCR, optionally cloned into a suitable vector, and subjected to DNA sequence analysis through methods well known to those of skill in the art. By comparing the DNA sequence of the mutant NHP allele to that of the normal NHP allele, the mutation(s) responsible for the loss or 10 alteration of function of the mutant NHP gene product can be ascertained.

Alternatively, a genomic library can be constructed using DNA obtained from an individual suspected of or known to carry the mutant NHP allele, or a cDNA library can be constructed using RNA 15 from a tissue known, or suspected, to express the mutant NHP allele. A normal NHP gene, or any suitable fragment thereof, can then be labeled and used as a probe to identify the corresponding mutant NHP allele in such libraries. Clones containing the mutant NHP gene sequences may then be purified and subjected to sequence 20 analysis according to methods well known to those of skill in the art.

Additionally, an expression library can be constructed utilizing cDNA synthesized from, for example, RNA isolated from a tissue known, or suspected, to express a mutant NHP allele in an 25 individual suspected of or known to carry such a mutant allele. In this manner, gene products made by the putatively mutant tissue may be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against the normal NHP product, as described, below, in Section 5.3. (For 30 screening techniques, see, for example, Harlow, E. and Lane, eds., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Press, Cold Spring Harbor.)

Additionally, screening can be accomplished by screening with labeled NHP fusion proteins, such as, for example, alkaline 35 phosphatase-NHP or NHP-alkaline phosphatase fusion proteins. In cases where a NHP mutation results in an expressed gene product with altered function (e.g., as a result of a missense or a

frameshift mutation), a polyclonal set of antibodies to NHP are likely to cross-react with the mutant NHP sequence product. Library clones detected via their reaction with such labeled antibodies can be purified and subjected to sequence analysis 5 according to methods well known to those of skill in the art.

The invention also encompasses nucleotide sequences that encode mutant NHPs, peptide fragments of the NHPs, truncated NHPs, and NHP fusion proteins. These include, but are not limited to nucleotide sequences encoding mutant NHPs described in section 5.2 10 *infra*; polypeptides or peptides corresponding to one or more domains of the NHP or portions of these domains; truncated NHPs in which one or more of the domains is deleted, or a truncated nonfunctional NHP. Nucleotides encoding fusion proteins may include, but are not limited to, full length NHP sequences, 15 truncated NHPs, or nucleotides encoding peptide fragments of a NHP fused to an unrelated protein or peptide, such as for example, a NHP domain fused to an Ig Fc domain which increases the stability and half life of the resulting fusion protein (e.g., NHP-Ig) in the bloodstream; or an enzyme such as a fluorescent protein or a 20 luminescent protein which can be used as a marker.

The invention also encompasses (a) DNA vectors that contain any of the foregoing NHP coding sequences and/or their complements (i.e., antisense); (b) DNA expression vectors that contain any of the foregoing NHP coding sequences operatively associated with a 25 regulatory element that directs the expression of the coding sequences; (c) genetically engineered host cells that contain any of the foregoing NHP coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences in the host cell; and (d) genetically engineered host 30 cells that express an endogenous NHP sequence under the control of an exogenously introduced regulatory element (i.e., gene activation).

As used herein, regulatory elements include, but are not limited to, inducible and non-inducible promoters, enhancers, 35 operators and other elements known to those skilled in the art that drive and regulate expression. Such regulatory elements include but are not limited to the human cytomegalovirus (hCMV)

immediate early gene, regulatable, viral elements (particularly retroviral LTR promoters), the early or late promoters of SV40 adenovirus, the *lac* system, the *trp* system, the TAC system, the TRC system, the major operator and promoter regions of phage 5 lambda, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase (PGK), the promoters of acid phosphatase, and the promoters of the yeast  $\alpha$ -mating factors.

### **5.2 NHP PROTEINS AND POLYPEPTIDES**

10 NHPs, polypeptides, peptide fragments, mutated, truncated, or deleted forms of the NHPs, and/or NHP fusion proteins can be prepared for a variety of uses. These uses include, but are not limited to, the generation of antibodies, as reagents in diagnostic assays, for the identification of other cellular 15 sequence products related to a NHP, as reagents in assays for screening for compounds that can be as pharmaceutical reagents useful in the therapeutic treatment of mental, biological, or medical disorders and disease.

20 The Sequence Listing discloses the amino acid sequences encoded by the described NHP sequences. The NHPs have initiator methionines in DNA sequence contexts consistent with translation initiation sites, followed by hydrophobic signal sequences typical of secreted proteins.

25 The NHP amino acid sequences of the invention include the nucleotide and amino acid sequences presented in the Sequence Listing as well as analogues and derivatives thereof. Further, corresponding NHP homologues from other species are encompassed by the invention. In fact, any NHP protein encoded by the NHP 30 nucleotide sequences described in Section 5.1, above, are within the scope of the invention, as are any novel polynucleotide sequences encoding all or any novel portion of an amino acid sequence presented in the Sequence Listing. The degenerate nature of the genetic code is well known, and, accordingly, each amino acid presented in the Sequence Listing, is generically 35 representative of the well known nucleic acid "triplet" codon, or in many cases codons, that can encode the amino acid. As such, as contemplated herein, the amino acid sequences presented in the

Sequence Listing, when taken together with the genetic code (see, for example, Table 4-1 at page 109 of "Molecular Cell Biology", 1986, J. Darnell *et al.* eds., Scientific American Books, New York, NY, herein incorporated by reference) are generically 5 representative of all the various permutations and combinations of nucleic acid sequences that can encode such amino acid sequences.

The invention also encompasses proteins that are functionally equivalent to the NHPs encoded by the nucleotide sequences described in Section 5.1, as judged by any of a number of 10 criteria, including, but not limited to, the ability to bind a receptor of a NHP, the ability to effect an identical or complementary signal transduction pathway, a change in cellular metabolism (e.g., ion flux, tyrosine phosphorylation, etc.), or change in phenotype when the NHP equivalent is similarly expressed 15 or mutated in an appropriate cell type (such as the amelioration, prevention or delay of a biochemical, biophysical, or overt phenotype). Such functionally equivalent NHP proteins include, but are not limited to, additions or substitutions of amino acid residues within the amino acid sequence encoded by the NHP 20 nucleotide sequences described above in Section 5.1, but which result in a silent change, thus producing a functionally equivalent gene product. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, 25 hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids 30 include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

While random mutations can be made to NHP DNA (using random mutagenesis techniques well known to those skilled in the art) and the resulting mutant NHPs tested for activity, site-directed 35 mutations of the NHP coding sequence can be engineered (using site-directed mutagenesis techniques well known to those skilled in the art) to generate mutant NHPs with increased function, e.g.,

higher receptor binding affinity, decreased function, and/or increased physiological half-life, and increased signal transduction triggering. One starting point for such analysis is by aligning the disclosed human sequences with corresponding 5 gene/protein sequences from, for example, other mammals in order to identify amino acid sequence motifs that are conserved between different species. Non-conservative changes can be engineered at variable positions to alter function, signal transduction capability, or both. Alternatively, where alteration of function 10 is desired, deletion or non-conservative alterations of the conserved regions (*i.e.*, identical amino acids) can be engineered. For example, deletion or non-conservative alterations (substitutions or insertions) of the various conserved transmembrane domains.

Other mutations to the NHP coding sequence can be made to generate NHPs that are better suited for expression, scale up, etc. in the host cells chosen. For example, cysteine residues can be deleted or substituted with another amino acid in order to 20 eliminate disulfide bridges; N-linked glycosylation sites can be altered or eliminated to achieve, for example, expression of a homogeneous product that is more easily recovered and purified from yeast hosts which are known to hyperglycosylate N-linked sites. To this end, a variety of amino acid substitutions at one or both of the first or third amino acid positions of any one or 25 more of the glycosylation recognition sequences which occur in the NHP (N-X-S or N-X-T), and/or an amino acid deletion at the second position of any one or more such recognition sequences in the NHP will prevent glycosylation of the NHP at the modified tripeptide sequence. (See, *e.g.*, Miyajima *et al.*, 1986, EMBO J. 5(6):1193-30 1197).

Peptides corresponding to one or more fragment or domain of a NHP, truncated or deleted NHPs, as well as fusion proteins in which a full length NHP, a NHP peptide, or truncated NHP is fused to an unrelated protein, are also within the scope of the 35 invention and can be designed on the basis of the presently disclosed NHP nucleotide and NHP amino acid sequences. Typically, a peptide can have as few as three amino acids, but preferably at

least about 6 amino acids, more preferably at least about 12 amino acids and up to about 80 amino acids. Fusion proteins include, but are not limited to, IgFc fusions which stabilize the NHP protein or peptide and prolong half-life *in vivo*; or fusions to 5 any amino acid sequence that allows the fusion protein to be anchored to the cell membrane; or fusions to an enzyme, fluorescent protein, or luminescent protein which provide a marker function.

While the NHPs and peptides can be chemically synthesized 10 (e.g., see Creighton, 1983, *Proteins: Structures and Molecular Principles*, W.H. Freeman & Co., N.Y.), large polypeptides derived from a NHP and full length NHPs can be advantageously produced by recombinant DNA technology using techniques well known in the art for expressing nucleic acid containing NHP sequences and/or coding sequences. Such methods can be used to construct expression 15 vectors containing a NHP nucleotide sequences described in Section 5.1 and appropriate transcriptional and translational control signals. These methods include, for example, *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* 20 genetic recombination. See, for example, the techniques described in Sambrook *et al.*, 1989, *supra*, and Ausubel *et al.*, 1989, *supra*. Alternatively, RNA corresponding to all or a portion of a 25 transcript encoded by a NHP nucleotide sequence may be chemically synthesized using, for example, synthesizers. See, for example, the techniques described in "Oligonucleotide Synthesis", 1984, Gait, M.J. ed., IRL Press, Oxford, which is incorporated by reference herein in its entirety.

A variety of host-expression vector systems may be utilized 30 to express the NHP nucleotide sequences of the invention. Where the NHP peptide or polypeptide is a soluble derivative, the peptide or polypeptide can be recovered from the culture, *i.e.*, from the host cell in cases where the NHP peptide or polypeptide is not secreted, and from the culture media in cases where the NHP peptide or polypeptide is secreted by the cells. However, such 35 expression systems also encompass engineered host cells that express a NHP, or functional equivalent, *in situ*, *i.e.*, anchored in the cell membrane. Purification or enrichment of NHP from such

expression systems can be accomplished using appropriate detergents and lipid micelles and methods well known to those skilled in the art. However, such engineered host cells themselves may be used in situations where it is important not 5 only to retain the structural and functional characteristics of the NHP, but to assess biological activity, e.g., in drug screening assays.

The expression systems that may be used for purposes of the invention include but are not limited to microorganisms such as 10 bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing NHP nucleotide sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing NHP nucleotide sequences; insect cell systems infected 15 with recombinant virus expression vectors (e.g., baculovirus) containing NHP sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing NHP nucleotide sequences; or mammalian cell systems 20 (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 25 7.5K promoter).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the NHP product being expressed. For example, when a large quantity of such a protein is to be produced for the generation of 30 pharmaceutical compositions of or containing NHP, or for raising antibodies to a NHP, vectors that direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., 1983, EMBO J. 35 2:1791), in which a NHP coding sequence may be ligated individually into the vector in frame with the *lacZ* coding region so that a fusion protein is produced; pIN vectors (Inouye &

Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such 5 fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The PGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the 10 GST moiety.

In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. A NHP coding sequence may be cloned individually into non-essential 05 regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of NHP coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the 20 proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect *Spodoptera frugiperda* cells in which the inserted sequence is expressed (e.g., see Smith et al., 1983, J. Virol. 46: 584; Smith, U.S. Patent No. 4,215,051).

25 In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the NHP nucleotide sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. 30 This chimeric sequence may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing a NHP product in infected hosts (e.g., See Logan & 35 Shenk, 1984, Proc. Natl. Acad. Sci. USA 81:3655-3659). Specific initiation signals may also be required for efficient translation of inserted NHP nucleotide sequences. These signals include the

ATG initiation codon and adjacent sequences. In cases where an entire NHP sequence or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may 5 be needed. However, in cases where only a portion of a NHP coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the 10 reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (See Bittner *et al.*, 25 1987, *Methods in Enzymol.* 153:516-544).

In addition, a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the sequence product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., 20 cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct 25 modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include, but are not limited to, 30 CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, human cell lines.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which 35 stably express the NHP sequences described above may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g.,

promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are 5 switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer 10 cell lines which express the NHP product. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the NHP product.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, et 15 al., 1977, *Cell* 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, *Proc. Natl. Acad. Sci. USA* 48:2026), and adenine phosphoribosyltransferase (Lowy, et al., 1980, *Cell* 22:817) genes 20 can be employed in tk<sup>-</sup>, hprt<sup>-</sup> or aprt<sup>-</sup> cells, respectively. Also, antimetabolite resistance can be used as the basis of selection 25 for the following genes: dhfr, which confers resistance to methotrexate (Wigler, et al., 1980, *Natl. Acad. Sci. USA* 77:3567; O'Hare, et al., 1981, *Proc. Natl. Acad. Sci. USA* 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, *Proc. Natl. Acad. Sci. USA* 78:2072); neo, which confers 30 resistance to the aminoglycoside G-418 (Colberre-Garapin, et al., 1981, *J. Mol. Biol.* 150:1); and hygro, which confers resistance to hygromycin (Santerre, et al., 1984, *Gene* 30:147).

Alternatively, any fusion protein may be readily purified by 35 utilizing an antibody specific for the fusion protein being expressed. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht, et al., 1991, *Proc. Natl. Acad. Sci. USA* 88: 8972-8976). In this system, the sequence of interest is subcloned into a vaccinia recombination plasmid 40 such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues.

Extracts from cells infected with recombinant vaccinia virus are loaded onto  $\text{Ni}^{2+}$ ·nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers. NHP products can also be expressed in transgenic animals. Animals of any species, including, but not limited to, worms, mice, rats, rabbits, guinea pigs, pigs, micro-pigs, birds, goats, and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate NHP transgenic animals.

Any technique known in the art may be used to introduce a NHP transgene into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to pronuclear microinjection (Hoppe, P.C. and Wagner, T.E., 1989, U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten *et al.*, 1985, Proc. Natl. Acad. Sci., USA 82:6148-6152); gene targeting in embryonic stem cells (Thompson *et al.*, 1989, Cell 56:313-321); electroporation of embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814); and sperm-mediated gene transfer (Lavitrano *et al.*, 1989, Cell 57:717-723); etc. For a review of such techniques, see Gordon, 1989, Transgenic Animals, Intl. Rev. Cytol. 115:171-229, which is incorporated by reference herein in its entirety.

The present invention provides for transgenic animals that carry the NHP transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, i.e., mosaic animals or somatic cell transgenic animals. The transgene may be integrated as a single transgene or in concatamers, e.g., head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko *et al.*, 1992, Proc. Natl. Acad. Sci. USA 89:6232-6236. The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

When it is desired that the NHP transgene be integrated into the chromosomal site of the endogenous NHP gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the

endogenous NHP gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous NHP gene (i.e., "knockout" animals).

5 The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous NHP gene in only that cell type, by following, for example, the teaching of Gu et al., 1994, *Science*, 265:103-106. The regulatory sequences required for such a cell-type specific inactivation will depend  
10 upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant NHP gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to assay whether integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include but are not limited to Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and RT-PCR. Samples of NHP gene-expressing tissue, may also be evaluated immunocytochemically using antibodies specific for the NHP transgene product.

25 **5.3 ANTIBODIES TO NHPs**

Antibodies that specifically recognize one or more epitopes of a NHP, or epitopes of conserved variants of a NHP, or peptide fragments of a NHP are also encompassed by the invention. Such  
30 antibodies include but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments,  $F(ab')_2$  fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the  
35 above.

The antibodies of the invention may be used, for example, in the detection of NHP in a biological sample and may, therefore, be utilized as part of a diagnostic or prognostic technique whereby

patients may be tested for abnormal amounts of NHP. Such antibodies may also be utilized in conjunction with, for example, compound screening schemes, as described, below, in Section 5.5, for the evaluation of the effect of test compounds on expression 5 and/or activity of a NHP gene product. Additionally, such antibodies can be used in conjunction gene therapy to, for example, evaluate the normal and/or engineered NHP-expressing cells prior to their introduction into the patient. Such antibodies may additionally be used as a method for the inhibition 10 of abnormal NHP activity. Thus, such antibodies may, therefore, be utilized as part of treatment methods.

For the production of antibodies, various host animals may be immunized by injection with the NHP, an NHP peptide (e.g., one corresponding to a functional domain of an NHP), truncated NHP 5 polypeptides (NHP in which one or more domains have been deleted), functional equivalents of the NHP or mutants of the NHP. Such host animals may include but are not limited to rabbits, mice, goats, and rats, to name but a few. Various adjuvants may be used to increase the immunological response, depending on the host 10 species, including but not limited to Freund's adjuvant (complete and incomplete), mineral salts such as aluminum hydroxide or aluminum phosphate, surface active substances such as lyssolecithin, pluronic polyols, polyanions, peptides, oil emulsions, and potentially useful human adjuvants such as BCG 20 (bacille Calmette-Guerin) and *Corynebacterium parvum*.

Alternatively, the immune response could be enhanced by combination and or coupling with molecules such as keyhole limpet 25 hemocyanin, tetanus toxoid, diphtheria toxoid, ovalbumin, cholera toxin or fragments thereof. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique which provides for the production of antibody molecules 30 by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975, Nature 256:495-497; and U.S. Patent No. 4,376,110), the human B-

cell hybridoma technique (Kosbor *et al.*, 1983, *Immunology Today* 4:72; Cole *et al.*, 1983, *Proc. Natl. Acad. Sci. USA* 80:2026-2030), and the EBV-hybridoma technique (Cole *et al.*, 1985, *Monoclonal Antibodies And Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96).

5 Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo. Production of high titers of mAbs in vivo makes this the presently preferred method of production.

10 In addition, techniques developed for the production of "chimeric antibodies" (Morrison *et al.*, 1984, *Proc. Natl. Acad. Sci.*, 81:6851-6855; Neuberger *et al.*, 1984, *Nature*, 312:604-608; Takeda *et al.*, 1985, *Nature*, 314:452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity 15 together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.

20 Such technologies are described in U.S. Patents Nos. 6,075,181 and 5,877,397 and their respective disclosures which are herein incorporated by reference in their entirety.

25 Alternatively, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778; Bird, 1988, *Science* 242:423-426; Huston *et al.*, 1988, *Proc. Natl. Acad. Sci. USA* 85:5879-5883; and Ward *et al.*, 1989, *Nature* 334:544-546) can be adapted to produce single chain antibodies against NHP gene products. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid 30 bridge, resulting in a single chain polypeptide.

35 Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, such fragments include, but are not limited to: the  $F(ab')_2$  fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the  $F(ab')_2$  fragments. Alternatively, Fab expression libraries may be constructed (Huse *et al.*, 1989, *Science*,

246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

Antibodies to a NHP can, in turn, be utilized to generate anti-idiotype antibodies that "mimic" a given NHP, using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, 1993, FASEB J 7(5):437-444; and Nissinoff, 1991, J. Immunol. 147(8):2429-2438). For example antibodies which bind to a NHP domain and competitively inhibit the binding of NHP to its cognate receptor can be used to generate anti-idiotypes that "mimic" the NHP and, therefore, bind and activate or neutralize a receptor. Such anti-idiotypic antibodies or Fab fragments of such anti-idiotypes can be used in therapeutic regimens involving the NHP signaling pathway.

#### **5.4 DIAGNOSIS OF ABNORMALITIES RELATED TO A NHP**

A variety of methods can be employed for the diagnostic and prognostic evaluation of disorders related to NHP function, and for the identification of subjects having a predisposition to such disorders.

Such methods may, for example, utilize reagents such as the NHP nucleotide sequences described in Section 5.1 and NHP antibodies as described in Section 5.3. Specifically, such reagents may be used, for example, for: (1) the detection of the presence of NHP gene mutations, or the detection of either over- or under-expression of NHP mRNA relative to a given phenotype; (2) the detection of either an over- or an under-abundance of NHP gene product relative to a given phenotype; and (3) the detection of perturbations or abnormalities in any potential signal transduction, metabolic, or catabolic pathway mediated by or involving a NHP.

The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one specific NHP nucleotide sequence or NHP antibody reagent described herein, which may be conveniently used, e.g., in clinical settings, to diagnose patients exhibiting body weight disorder abnormalities.

For the detection of NHP mutations, any nucleated cell can be used as a starting source for genomic nucleic acid. For the detection of NHP gene expression or NHP gene products, any cell type or tissue in which the NHP sequence is expressed, such as, 5 for example, brain cells, may be utilized.

Nucleic acid-based detection techniques are described, below, in Section 5.4.1. Peptide detection techniques are described, below, in Section 5.4.2.

10 **5.4.1 DETECTION OF NHP SEQUENCES AND TRANSCRIPTS**

Mutations within a NHP sequence can be detected by utilizing a number of techniques. Nucleic acid from any nucleated cell can be used as the starting point for such assay techniques, and may 15 be isolated according to standard nucleic acid preparation procedures which are well known to those of skill in the art.

DNA may be used in hybridization or amplification assays of biological samples to detect abnormalities involving NHP gene structure, including point mutations, insertions, deletions and 20 chromosomal rearrangements. Such assays may include, but are not limited to, Southern analyses, single stranded conformational polymorphism analyses (SSCP), and PCR analyses.

Such diagnostic methods for the detection of NHP gene-specific mutations can involve for example, contacting and 25 incubating nucleic acids including recombinant DNA molecules, cloned genes or degenerate variants thereof, obtained from a sample, e.g., derived from a patient sample or other appropriate cellular source, with one or more labeled nucleic acid reagents including recombinant DNA molecules, cloned genes or degenerate 30 variants thereof, as described in Section 5.1, under conditions favorable for the specific annealing of these reagents to their complementary sequences within a given NHP gene. Preferably, the lengths of these nucleic acid reagents are at least about 15 to about 30 nucleotides. After incubation, all non-annealed nucleic 35 acids are removed from the nucleic acid:NHP molecule hybrid. The presence of nucleic acids which have hybridized, if any such molecules exist, is then detected. Using such a detection scheme, the nucleic acid from the cell type or tissue of interest can be

immobilized, for example, to a solid support such as a membrane, or a plastic surface such as that on a microtiter plate or polystyrene beads. In this case, after incubation, non-annealed, labeled nucleic acid reagents of the type described in Section 5.1  
5 are easily removed. Detection of the remaining, annealed, labeled NHP nucleic acid reagents is accomplished using standard techniques well-known to those in the art. The NHP sequences to which the nucleic acid reagents have annealed can be compared to the annealing pattern expected from a normal NHP sequence in order  
10 to determine whether a NHP gene mutation is present.

Alternative diagnostic methods for the detection of NHP gene specific nucleic acid molecules, in patient samples or other appropriate cell sources, may involve their amplification, e.g., by PCR (the experimental embodiment set forth in Mullis, K.B.,  
15 1987, U.S. Patent No. 4,683,202), followed by the detection of the amplified molecules using techniques well known to those of skill in the art. The resulting amplified sequences can be compared to those which would be expected if the nucleic acid being amplified contained only normal copies of a NHP gene in order to determine  
20 whether a NHP gene mutation exists.

Additionally, well-known genotyping techniques can be performed to identify individuals carrying NHP gene mutations. Such techniques include, for example, the use of restriction fragment length polymorphisms (RFLPs), which involve sequence  
25 variations in one of the recognition sites for the specific restriction enzyme used.

Additionally, improved methods for analyzing DNA polymorphisms which can be utilized for the identification of NHP gene mutations have been described which capitalize on the  
30 presence of variable numbers of short, tandemly repeated DNA sequences between the restriction enzyme sites. For example, Weber (U.S. Pat. No. 5,075,217, which is incorporated herein by reference in its entirety) describes a DNA marker based on length polymorphisms in blocks of (dC-dA)<sub>n</sub>-(dG-dT)<sub>n</sub> short tandem repeats.  
35 The average separation of (dC-dA)<sub>n</sub>-(dG-dT)<sub>n</sub> blocks is estimated to be 30,000-60,000 bp. Markers which are so closely spaced exhibit a high frequency co-inheritance, and are extremely useful in the

identification of genetic mutations, such as, for example, mutations within a given NHP gene, and the diagnosis of diseases and disorders related to NHP mutations.

Also, Caskey *et al.* (U.S. Pat. No. 5,364,759, which is 5 incorporated herein by reference in its entirety) describe a DNA profiling assay for detecting short tri and tetra nucleotide repeat sequences. The process includes extracting the DNA of interest, such as the NHP gene, amplifying the extracted DNA, and labeling the repeat sequences to form a genotypic map of the 10 individual's DNA.

The level of NHP gene expression can also be assayed by detecting and measuring NHP transcription. For example, RNA from a cell type or tissue known, or suspected to express the NHP sequence, such as brain, may be isolated and tested utilizing 15 hybridization or PCR techniques such as are described, above. The isolated cells can be derived from cell culture or from a patient. The analysis of cells taken from culture may be a necessary step in the assessment of cells to be used as part of a cell-based gene 20 therapy technique or, alternatively, to test the effect of compounds on the expression of the NHP sequence. Such analyses may reveal both quantitative and qualitative aspects of the expression pattern of the NHP gene, including activation or inactivation of NHP gene expression.

In one embodiment of such a detection scheme, cDNAs are 25 synthesized from the RNAs of interest (e.g., by reverse transcription of the RNA molecule into cDNA). A sequence within the cDNA is then used as the template for a nucleic acid amplification reaction, such as a PCR amplification reaction, or the like. The nucleic acid reagents used as synthesis initiation 30 reagents (e.g., primers) in the reverse transcription and nucleic acid amplification steps of this method are chosen from among the NHP nucleic acid reagents described in Section 5.1. The preferred lengths of such nucleic acid reagents are at least about 9-30 nucleotides. For detection of the amplified product, the nucleic 35 acid amplification may be performed using radioactively or non-radioactively labeled nucleotides. Alternatively, enough amplified product may be made such that the product may be

visualized by standard ethidium bromide staining, by utilizing any other suitable nucleic acid staining method, or by sequencing.

Additionally, it is possible to perform such NHP gene expression assays "in situ", *i.e.*, directly upon tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections, such that no nucleic acid purification is necessary. Nucleic acid reagents such as those described in Section 5.1 may be used as probes and/or primers for such *in situ* procedures (See, for example, Nuovo, G.J., 1992, "PCR *In Situ* Hybridization: Protocols And Applications", Raven Press, NY).

Alternatively, if a sufficient quantity of the appropriate cells can be obtained, standard Northern analysis can be performed to determine the level and tissue distribution of mRNA expression of a NHP gene.

#### **5.4.2 DETECTION OF NHP GENE PRODUCTS**

Antibodies directed against wild type or mutant NHP gene products or conserved variants or peptide fragments thereof, which are discussed, above, in Section 5.3, may also be used as diagnostics and prognostics, as described herein. Such diagnostic methods, may be used to detect abnormalities in the level of NHP gene expression, or abnormalities in the structure and/or temporal, tissue, cellular, or subcellular location of the NHP, and may be performed *in vivo* or *in vitro*, such as, for example, on biopsy tissue.

For example, antibodies directed to epitopes of an NHP can be used *in vivo* to detect the pattern and level of expression of the NHP in the body. Such antibodies can be labeled, *e.g.*, with a radio-opaque or other appropriate compound and injected into a subject in order to visualize binding to the NHP expressed in the body using methods such as X-rays, CAT-scans, or MRI. Labeled antibody fragments, *e.g.*, the Fab or single chain antibody comprising the smallest portion of the antigen binding region, are preferred for this purpose to promote crossing the blood-brain barrier and permit labeling of NHPs expressed in the brain.

Additionally, any NHP fusion protein or NHP conjugated protein whose presence can be detected, can be administered. For

example, NHP fusion or conjugated proteins labeled with a radio-opaque or other appropriate compound can be administered and visualized *in vivo*, as discussed, above for labeled antibodies. Further such NHP fusion proteins (such as alkaline phosphatase-5 NHP or NHP-alkaline phosphatase) can be utilized for *in vitro* diagnostic procedures.

Alternatively, immunoassays or fusion protein detection assays, as described above, can be utilized on biopsy and autopsy samples *in vitro* to permit assessment of the expression pattern of 10 the NHP. Such assays are not confined to the use of antibodies that define a NHP domain, but can include the use of antibodies directed to epitopes of any domain of a NHP. The use of each or all of these labeled antibodies will yield useful information regarding translation and intracellular transport of the NHP to 15 the cell surface and can identify defects in processing.

The tissue or cell type to be analyzed will generally include those which are known, or suspected, to express the NHP sequence, such as, for example, epithelial cells, kidney cells, placenta cells, brain cells, etc. The protein isolation methods employed 20 herein may, for example, be such as those described in Harlow and Lane (Harlow, E. and Lane, D., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York), which is incorporated herein by reference in its 25 entirety. The isolated cells can be derived from cell culture or from a patient. The analysis of cells taken from culture may be a necessary step in the assessment of cells that could be used as part of a cell-based gene therapy technique or, alternatively, to test the effect of compounds on the expression of a NHP sequence.

For example, antibodies, or fragments of antibodies, such as 30 those described above in Section 5.3 are useful in the present invention, and may be used to quantitatively or qualitatively detect the presence of NHP products, or conserved variants or peptide fragments thereof. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled 35 antibody (see below, this Section) coupled with light microscopic, flow cytometric, or fluorimetric detection. Such techniques are

especially preferred if such NHP products are at least transiently present on the cell surface.

The antibodies (or fragments thereof) or NHP fusion or conjugated proteins useful in the present invention may,

5 additionally, be employed histologically, as in immunofluorescence, immunoelectron microscopy or non-immuno assays, for *in situ* detection of NHP gene products or conserved variants or peptide fragments thereof, or to assay NHP binding (in the case of labeled NHP-fusion protein).

10 *In situ* detection may be accomplished by removing a histological specimen from a patient, and applying thereto a labeled antibody or fusion protein of the present invention. The antibody (or fragment) or fusion protein is preferably applied by overlaying the labeled antibody (or fragment) onto a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of the NHP product, or conserved variants or peptide fragments, or NHP binding, but also its distribution in the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of a wide 20 variety of histological methods (such as staining procedures) can be modified in order to achieve such *in situ* detection.

25 Immunoassays and non-immunoassays for NHP products, or conserved variants or peptide fragments thereof, will typically comprise incubating a sample, such as a biological fluid, a tissue extract, freshly harvested cells, or lysates of cells which have been incubated in cell culture, in the presence of a detectably labeled antibody capable of identifying NHP products or conserved variants or peptide fragments thereof, and detecting the bound antibody by any of a number of techniques well-known in the art. 30 Alternatively, the labeled antibody can be directed against an antigenic tag that has been directly or indirectly attached to a NHP.

35 The biological sample may be brought in contact with and immobilized onto a solid phase support or carrier such as nitrocellulose, or other solid support which is capable of immobilizing cells, cell particles or soluble proteins. The support may then be washed with suitable buffers followed by

treatment with the detectably labeled NHP antibody or NHP receptor fusion protein. The solid phase support may then be washed with the buffer a second time to remove unbound antibody or fusion protein. The amount of bound label on solid support may then be  
5 detected by conventional means.

By "solid phase support or carrier" is intended any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amyloses, natural and modified  
10 celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material may have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or  
15 antibody. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc. Preferred supports include polystyrene beads. Those skilled in the art will know  
20 many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.

The binding activity of a given lot of NHP antibody or NHP ligand fusion protein may be determined according to well known  
25 methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.

With respect to antibodies, one of the ways in which the NHP antibody can be detectably labeled is by linking the same to an  
30 enzyme and use in an enzyme immunoassay (EIA) (Voller, A., "The Enzyme Linked Immunosorbent Assay (ELISA)", 1978, Diagnostic Horizons 2:1-7, Microbiological Associates Quarterly Publication, Walkersville, MD); Voller, A. et al., 1978, J. Clin. Pathol. 31:507-520; Butler, J.E., 1981, Meth. Enzymol. 73:482-523; Maggio,  
35 E. (ed.), 1980, Enzyme Immunoassay, CRC Press, Boca Raton, FL.; Ishikawa, E. et al., (eds.), 1981, Enzyme Immunoassay, Kgaku Shoin, Tokyo). The enzyme that is bound to the antibody will

react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorimetric or by visual means. Enzymes which can be used to detectably label 5 the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate, dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-10 galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. The detection can be accomplished by colorimetric methods which employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic 15 reaction of a substrate in comparison with similarly prepared standards.

20 Detection may also be accomplished using any of a variety of other immunoassays. For example, by radioactively labeling the antibodies or antibody fragments, it is possible to detect NHP through the use of a radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, 25 March, 1986, which is incorporated by reference herein). The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography.

It is also possible to label the antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent 30 labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin,  $\alpha$ -phthaldehyde and fluorescamine.

The antibody can also be detectably labeled using fluorescence emitting metals such as  $^{152}\text{Eu}$ , or others of the 35 lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriaminepentacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a 5 chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

Likewise, a bioluminescent compound may be used to label the 10 antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in, which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important 15 bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

#### **5.5 SCREENING ASSAYS FOR COMPOUNDS THAT MODULATE NHP EXPRESSION OR ACTIVITY**

The following assays are designed to identify compounds that interact with (e.g., bind to) NHPs, compounds that interfere with the interaction of an NHP with its receptor, and to compounds that modulate the activity of NHP gene expression (i.e., modulate the 20 level of NHP gene expression) or modulate the levels of NHP in the body. Assays may additionally be utilized which identify compounds that bind to NHP gene regulatory sequences (e.g., promoter sequences) and, consequently, may modulate NHP gene 25 expression. See e.g., Platt, K.A., 1994, J. Biol. Chem. 269:28558-28562, which is incorporated herein by reference in its 30 entirety.

The compounds which may be screened in accordance with the invention include but are not limited to peptides, antibodies and fragments thereof, and other organic compounds (e.g., 35 peptidomimetics) that bind to a NHP and either mimic the activity triggered by the natural product (i.e., agonists) or inhibit the activity triggered by the natural ligand (i.e., antagonists); as well as peptides, antibodies or fragments thereof, and other

organic compounds that mimic the NHP (or a portion thereof) and bind to and "activate" or "neutralize" the natural receptor.

Such compounds may include, but are not limited to, peptides such as, for example, soluble peptides, including but not limited to members of random peptide libraries; (see, e.g., Lam, K.S. et al., 1991, *Nature* 354:82-84; Houghten, R. et al., 1991, *Nature* 354:84-86), and combinatorial chemistry-derived molecular library made of D- and/or L- configuration amino acids, phosphopeptides (including, but not limited to members of random or partially degenerate, directed phosphopeptide libraries; see, e.g., Songyang, Z. et al., 1993, *Cell* 72:767-778), antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and FAb, F(ab')<sub>2</sub> and FAb expression library fragments, and epitope-binding fragments thereof), and small organic or inorganic molecules.

Other compounds which can be screened in accordance with the invention include but are not limited to small organic molecules that are able to cross the blood-brain barrier, gain entry into an appropriate cell (e.g., in the choroid plexus, pituitary, the hypothalamus, etc.) and affect the expression of a NHP gene or some other gene involved in a NHP mediated pathway (e.g., by interacting with the regulatory region or transcription factors involved in gene expression); or such compounds that affect or substitute for the activity of the NHP or the activity of some other intracellular factor involved in a NHP signal transduction, catabolic, or metabolic pathways.

Computer modeling and searching technologies permit identification of compounds, or the improvement of already identified compounds, that can modulate NHP expression or activity. Having identified such a compound or composition, the active sites or regions are identified. Such active sites might typically be ligand binding sites. The active site can be identified using methods known in the art including, for example, from the amino acid sequences of peptides, from the nucleotide sequences of nucleic acids, or from study of complexes of the relevant compound or composition with its natural ligand. In the latter case, chemical or X-ray crystallographic methods can be

used to find the active site by finding where on the factor the complexed ligand is found.

Next, the three dimensional geometric structure of the active site is determined. This can be done by known methods, including 5 X-ray crystallography, which can determine a complete molecular structure. On the other hand, solid or liquid phase NMR can be used to determine certain intra-molecular distances. Any other experimental method of structure determination can be used to obtain partial or complete geometric structures. The geometric 10 structures may be measured with a complexed ligand, natural or artificial, which may increase the accuracy of the active site structure determined.

If an incomplete or insufficiently accurate structure is determined, the methods of computer based numerical modeling can 15 be used to complete the structure or improve its accuracy. Any recognized modeling method may be used, including parameterized models specific to particular biopolymers such as proteins or nucleic acids, molecular dynamics models based on computing molecular motions, statistical mechanics models based on thermal 20 ensembles, or combined models. For most types of models, standard molecular force fields, representing the forces between constituent atoms and groups, are necessary, and can be selected from force fields known in physical chemistry. The incomplete or 25 less accurate experimental structures can serve as constraints on the complete and more accurate structures computed by these modeling methods.

Finally, having determined the structure of the active site (or binding site), either experimentally, by modeling, or by a combination, candidate modulating compounds can be identified by 30 searching databases containing compounds along with information on their molecular structure. Such a search seeks compounds having structures that match the determined active site structure and that interact with the groups defining the active site. Such a search can be manual, but is preferably computer assisted. These 35 compounds found from this search are potential NHP modulating compounds.

Alternatively, these methods can be used to identify improved modulating compounds from an already known modulating compound or ligand. The composition of the known compound can be modified and the structural effects of modification can be determined using the 5 experimental and computer modeling methods described above applied to the new composition. The altered structure is then compared to the active site structure of the compound to determine if an improved fit or interaction results. In this manner systematic variations in composition, such as by varying side groups, can be 10 quickly evaluated to obtain modified modulating compounds or ligands of improved specificity or activity.

Further experimental and computer modeling methods useful to identify modulating compounds based upon identification of the active sites (or binding sites) of a NHP, and related transduction 15 and transcription factors will be apparent to those of skill in the art.

Examples of molecular modeling systems are the CHARMM and QUANTA programs (Polygen Corporation, Waltham, MA). CHARMM performs the energy minimization and molecular dynamics functions. 20 QUANTA performs the construction, graphic modeling and analysis of molecular structure. QUANTA allows interactive construction, modification, visualization, and analysis of the behavior of molecules with each other.

A number of articles review computer modeling of drugs 25 interactive with specific proteins, such as Rotivinen, *et al.*, 1988, *Acta Pharmaceutical Fennica* 97:159-166; Ripka, *New Scientist* 54-57 (June 16, 1988); McKinlay and Rossmann, 1989, *Annu. Rev. Pharmacol. Toxicol.* 29:111-122; Perry and Davies, *OSAR: Quantitative Structure-Activity Relationships in Drug Design* 30 pp. 189-193 (Alan R. Liss, Inc. 1989); Lewis and Dean, 1989 *Proc. R. Soc. Lond.* 236:125-140 and 141-162; and, with respect to a model receptor for nucleic acid components, Askew, *et al.*, 1989, *J. Am. Chem. Soc.* 111:1082-1090. Other computer programs that 35 screen and graphically depict chemicals are available from companies such as BioDesign, Inc. (Pasadena, CA.), Allelix, Inc. (Mississauga, Ontario, Canada), and Hypercube, Inc. (Cambridge, Ontario). Although these are primarily designed for application

to drugs specific to particular proteins, they can be adapted to design of drugs specific to regions of DNA or RNA, once that region is identified.

Although described above with reference to design and

5 generation of compounds which could alter binding, one could also screen libraries of known compounds, including natural products or synthetic chemicals, and biologically active materials, including proteins, for compounds which are inhibitors or activators.

Cell-based systems can also be used to identify compounds

10 that bind (or mimic) NHPs as well as assess the altered activity associated with such binding in living cells. One tool of particular interest for such assays is green fluorescent protein which is described, *inter alia*, in U.S. Patent No. 5,625,048, herein incorporated by reference. Cells that may be used in such 15 cellular assays include, but are not limited to, leukocytes, or cell lines derived from leukocytes, lymphocytes, stem cells, including embryonic stem cells, and the like. In addition, expression host cells (e.g., B95 cells, COS cells, CHO cells, OMK cells, fibroblasts, Sf9 cells) genetically engineered to express a 20 functional NHP of interest and to respond to activation by the test, or natural, ligand, as measured by a chemical or phenotypic change, or induction of another host cell gene, can be used as an end point in the assay.

Compounds identified via assays such as those described

25 herein may be useful, for example, in elucidating the biological function of a NHP gene product. Such compounds can be administered to a patient at therapeutically effective doses to treat any of a variety of physiological or mental disorders. A 30 therapeutically effective dose refers to that amount of the compound sufficient to result in any amelioration, impediment, prevention, or alteration of any biological symptom.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD<sub>50</sub> (the dose 35 lethal to 50% of the population) and the ED<sub>50</sub> (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic

index and it can be expressed as the ratio LD<sub>50</sub>/ED<sub>50</sub>. Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds 5 to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a 10 range of circulating concentrations that include the ED<sub>50</sub> with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated 15 initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC<sub>50</sub> (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more 20 accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using 25 one or more physiologically acceptable carriers or excipients. Thus, the compounds and their physiologically acceptable salts and solvates may be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral, intracranial, intrathecal, or rectal 30 administration.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, 35 polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica);

disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, 5 syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or 10 hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring 15 and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

20 For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, 25 dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the 30 compound and a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added 35 preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing

and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

5 The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such 10 long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as 15 sparingly soluble derivatives, for example, as a sparingly soluble salt.

The compositions may, if desired, be presented in a pack or 20 dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

#### 5.5.1 *IN VITRO* SCREENING ASSAYS FOR COMPOUNDS THAT BIND TO NHPs

25 *In vitro* systems may be designed to identify compounds capable of interacting with (e.g., binding to) or mimicking NHPs. The compounds identified can be useful, for example, in modulating 30 the activity of wild type and/or mutant NHP gene products; can be useful in elaborating the biological function of the NHP; can be utilized in screens for identifying compounds that disrupt normal NHP interactions; or may themselves disrupt or activate such interactions.

35 The principle of the assays used to identify compounds that bind to NHPs, or NHP receptors, involves preparing a reaction mixture of an NHP and the test compound under conditions and for a time sufficient to allow the two components to interact and bind,

thus forming a complex which can be removed and/or detected in the reaction mixture. The NHP species used can vary depending upon the goal of the screening assay. For example, where agonists of the natural receptor are desired, the full length NHP, or a 5 soluble truncated NHP, a peptide, or fusion protein containing one or more NHP domains fused to a protein or polypeptide that affords advantages in the assay system (e.g., labeling, isolation of the resulting complex, etc.) can be utilized. Where compounds that directly interact with the NHP are sought, peptides corresponding 10 to the NHP and fusion proteins containing NHPs can be used.

The screening assays can be conducted in a variety of ways. For example, one method to conduct such an assay would involve anchoring the NHP, polypeptide, peptide, or fusion protein therefrom, or the test substance onto a solid phase and detecting 15 NHP/test compound complexes anchored on the solid phase at the end of the reaction. In one embodiment of such a method, the NHP reactant may be anchored onto a solid surface, and the test compound, which is not anchored, may be labeled, either directly or indirectly.

20 In practice, microtiter plates may conveniently be utilized as the solid phase. The anchored component may be immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished by simply coating the solid surface with a solution of the protein and drying. Alternatively, an immobilized 25 antibody, preferably a monoclonal antibody, specific for the protein to be immobilized may be used to anchor the protein to the solid surface. The surfaces may be prepared in advance and stored.

In order to conduct the assay, the nonimmobilized component 30 is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized on the solid surface. The detection of 35 complexes anchored on the solid surface can be accomplished in a number of ways. Where the previously nonimmobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously

nonimmobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the previously nonimmobilized component (the antibody, in turn, may be directly labeled or 5 indirectly labeled with a labeled anti-Ig antibody).

Alternatively, a reaction can be conducted in a liquid phase, the reaction products separated from unreacted components, and complexes detected; e.g., using an immobilized antibody specific for a NHP protein, polypeptide, peptide or fusion protein or the 10 test compound to anchor any complexes formed in solution, and a labeled antibody specific for the other component of the possible complex to detect anchored complexes.

Alternatively, cell-based assays can be used to identify 15 compounds that interact with NHP. To this end, cell lines that express NHP or NHP receptor, or cell lines (e.g., COS cells, CHO cells, fibroblasts, etc.) that have been genetically engineered to express NHP or NHP receptor (e.g., by transfection or transduction of NHP DNA) can be used. Interaction of the test compound with, for example, a NHP receptor expressed by the host cell can be 20 determined by comparison or competition with native NHP.

#### **5.5.2 ASSAYS FOR INTRACELLULAR PROTEINS THAT ARE ACTIVATED BY NHP BINDING**

Any method suitable for detecting protein-protein 25 interactions may be employed for identifying transmembrane proteins or intracellular proteins that interact with a NHP receptor. Among the traditional methods which may be employed are co-immunoprecipitation, crosslinking and co-purification through 30 gradients or chromatographic columns of cell lysates or proteins obtained from cell lysates and a NHP receptor to identify proteins in the lysate that interact with the NHP receptor. For these assays, the NHP component can be a full length NHP receptor, a soluble derivative lacking the membrane-anchoring region (e.g., a 35 truncated NHP receptor in which a TM is deleted resulting in a truncated molecule containing a ECD fused to a CD), a peptide corresponding to a CD or a fusion protein containing a CD of a NHP receptor. Once isolated, such an intracellular protein can be

P050960  
DRAFT-04-02-00

identified and can, in turn, be used, in conjunction with standard techniques, to identify proteins with which it interacts. For example, at least a portion of the amino acid sequence of an intracellular protein which interacts with a NHP receptor can be ascertained using techniques well known to those of skill in the art, such as via the Edman degradation technique. (See, e.g., Creighton, 1983, "Proteins: Structures and Molecular Principles", W.H. Freeman & Co., N.Y., pp.34-49). The amino acid sequence obtained may be used as a guide for the generation of oligonucleotide mixtures that can be used to screen for gene sequences encoding such intracellular proteins. Screening may be accomplished, for example, by standard hybridization or PCR techniques. Techniques for the generation of oligonucleotide mixtures and the screening are well-known. (See, e.g., Ausubel, *supra*, and PCR Protocols: A Guide to Methods and Applications, 1990, Innis, M. et al., eds. Academic Press, Inc., New York).

Additionally, methods may be employed which result in the simultaneous identification of genes that encode the transmembrane or intracellular proteins interacting with the NHP receptor. These methods include, for example, probing expression, libraries, in a manner similar to the well known technique of antibody probing of λgt11 libraries, using labeled NHP protein, or an NHP polypeptide, peptide or fusion protein, e.g., an NHP polypeptide or NHP domain fused to a marker (e.g., an enzyme, fluor, luminescent protein, or dye), or an Ig-Fc domain.

One method which detects protein interactions *in vivo*, the two-hybrid system, is described in detail for illustration only and not by way of limitation. One version of this system has been described (Chien et al., 1991, Proc. Natl. Acad. Sci. USA, 88:9578-9582) and is commercially available from Clontech (Palo Alto, CA).

Briefly, utilizing such a system, plasmids are constructed that encode two hybrid proteins: one plasmid consists of nucleotides encoding the DNA-binding domain of a transcription activator protein fused to a nucleotide sequence encoding an NHP receptor, an NHP, or polypeptide, peptide, or fusion protein therefrom, and the other plasmid consists of nucleotides encoding

the transcription activator protein's activation domain fused to a cDNA encoding an unknown protein which has been recombined into this plasmid as part of a cDNA library. The DNA-binding domain fusion plasmid and the cDNA library are transformed into a strain 5 of the yeast *Saccharomyces cerevisiae* that contains a reporter gene (e.g., HBS or *lacZ*) whose regulatory region contains the transcription activator's binding site. Either hybrid protein alone cannot activate transcription of the reporter gene: the DNA-binding domain hybrid cannot because it does not provide 10 activation function and the activation domain hybrid cannot because it cannot localize to the activator's binding sites. Interaction of the two hybrid proteins reconstitutes the functional activator protein and results in expression of the reporter gene, which is detected by an assay for the reporter gene 15 product.

The two-hybrid system or related methodology may be used to screen activation domain libraries for proteins that interact with the "bait" gene product. By way of example, and not by way of limitation, a NHP or NHP receptor can be used as the bait gene product. Total genomic or cDNA sequences are fused to the DNA 20 encoding an activation domain. This library and a plasmid encoding a hybrid of a bait NHP gene product fused to the DNA-binding domain are cotransformed into a yeast reporter strain, and the resulting transformants are screened for those that express 25 the reporter gene. For example, and not by way of limitation, a bait NHP gene sequence, such as the open reading frame of a NHP (or a domain of a NHP) can be cloned into a vector such that it is translationally fused to the DNA encoding the DNA-binding domain of the GAL4 protein. These colonies are purified and the library 30 plasmids responsible for reporter gene expression are isolated. DNA sequencing is then used to identify the proteins encoded by the library plasmids.

A cDNA library of the cell line from which proteins that interact with bait NHP gene product are to be detected can be made 35 using methods routinely practiced in the art. According to the particular system described herein, for example, the cDNA fragments can be inserted into a vector such that they are

translationally fused to the transcriptional activation domain of GAL4. This library can be co-transformed along with the bait NHP gene-GAL4 fusion plasmid into a yeast strain which contains a lacZ gene driven by a promoter which contains GAL4 activation sequence.

5 A cDNA encoded protein, fused to GAL4 transcriptional activation domain, that interacts with bait NHP gene product will reconstitute an active GAL4 protein and thereby drive expression of the HIS3 gene. Colonies which express HIS3 can be detected by their growth on petri dishes containing semi-solid agar based  
10 media lacking histidine. The cDNA can then be purified from these strains, and used to produce and isolate the bait NHP gene-interacting protein using techniques routinely practiced in the art.

15 **5.5.3 ASSAYS FOR COMPOUNDS THAT INTERFERE WITH NHP  
RECEPTOR/INTRACELLULAR OR NHP/TRANSMEMBRANE MACROMOLECULE  
INTERACTION**

20 Macromolecules that interact with NHPs or NHP receptors are referred to, for purposes of this discussion, as "binding partners". These binding partners are likely to be involved in the NHP mediated biological pathways. Therefore, it is desirable to identify compounds that interfere with or disrupt the interaction of such binding partners which may be useful in  
25 regulating or augmenting NHP activity in the body and/or controlling disorders associated with NHP activity (or a deficiency thereof).

30 The basic principle of the assay systems used to identify compounds that interfere with the interaction between a NHP or NHP receptor (collectively, the NHP moiety), and its binding partner or partners involves preparing a reaction mixture containing NHP or NHP receptor, or NHP polypeptides, peptides or fusion proteins as described in Sections 5.5.1 and 5.5.2 above, and the binding partner under conditions and for a time sufficient to allow the  
35 two to interact and bind, thus forming a complex. In order to test a compound for inhibitory activity, the reaction mixture is prepared in the presence and absence of the test compound. The test compound may be initially included in the reaction mixture, or may be added at a time subsequent to the addition of the NHP

moiety and its binding partner. Control reaction mixtures are incubated without the test compound or with a placebo. The formation of any complexes between the NHP moiety and the binding partner is then detected. The formation of a complex in the 5 control reaction, but not in the reaction mixture containing the test compound, indicates that the compound interferes with the interaction of the NHP moiety and the interactive binding partner. Additionally, complex formation within reaction mixtures containing the test compound and normal NHP protein may also be 10 compared to complex formation within reaction mixtures containing the test compound and a mutant NHP. This comparison may be important in those cases wherein it is desirable to identify compounds that specifically disrupt interactions of mutant, or mutated, NHPs but not normal NHPs.

15 The assay for compounds that interfere with the interaction of the NHP and binding partners can be conducted in a heterogeneous or homogeneous format. Heterogeneous assays involve anchoring either the NHP moiety or the binding partner onto a solid phase and detecting complexes anchored on the solid phase at the end of the reaction. In homogeneous assays, the entire 20 reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the compounds being tested. For example, test compounds that interfere with the interaction by 25 competition can be identified by conducting the reaction in the presence of the test substance; *i.e.*, by adding the test substance to the reaction mixture prior to, or simultaneously with, a NHP moiety and interactive binding partner. Alternatively, test compounds that disrupt preformed complexes, *e.g.* compounds with 30 higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed. The various formats are described briefly below.

35 In a heterogeneous assay system, either a NHP moiety or an interactive binding partner, is anchored onto a solid surface, while the non-anchored species is labeled, either directly or indirectly. In practice, microtiter plates are conveniently

utilized. The anchored species may be immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished simply by coating the solid surface with a solution of the NHP moiety or binding partner and drying. Alternatively, 5 an immobilized antibody specific for the species to be anchored may be used to anchor the species to the solid surface. The surfaces may be prepared in advance and stored.

In order to conduct the assay, the partner of the immobilized species is exposed to the coated surface with or without the test 10 compound. After the reaction is complete, unreacted components are removed (e.g., by washing) and any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the non-immobilized species is pre-labeled, 15 the detection of label immobilized on the surface indicates that complexes were formed. Where the non-immobilized species is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the initially non-immobilized species (the antibody, in turn, 20 may be directly labeled or indirectly labeled with a labeled anti-Ig antibody). Depending upon the order of addition of reaction components, test compounds which inhibit complex formation or which disrupt preformed complexes can be detected.

Alternatively, the reaction can be conducted in a liquid 25 phase in the presence or absence of the test compound, the reaction products separated from unreacted components, and complexes detected; e.g., using an immobilized antibody specific for one of the binding components to anchor any complexes formed in solution, and a labeled antibody specific for the other partner 30 to detect anchored complexes. Again, depending upon the order of addition of reactants to the liquid phase, test compounds which inhibit complex or which disrupt preformed complexes can be identified.

In an alternate embodiment of the invention, a homogeneous 35 assay can be used. In this approach, a preformed complex of a NHP moiety and an interactive binding partner is prepared in which either the NHP moiety or its binding partners is labeled, but the

signal generated by the label is quenched due to formation of the complex (see, e.g., U.S. Patent No. 4,190,496 by Rubenstein which utilizes this approach for immunoassays). The addition of a test substance that competes with and displaces one of the species from the preformed complex will result in the generation of a signal above background. In this way, test substances which disrupt NHP/intracellular binding partner interaction can be identified.

In a particular embodiment, a NHP fusion can be prepared for immobilization. For example, a NHP or a peptide fragment can be fused to a glutathione-S-transferase (GST) gene using a fusion vector, such as pGEX-5X-1, in such a manner that its binding activity is maintained in the resulting fusion protein. The interactive binding partner can be purified and used to raise a monoclonal antibody, using methods routinely practiced in the art and described above, in Section 5.3. This antibody can be labeled with the radioactive isotope  $^{125}\text{I}$ , for example, by methods routinely practiced in the art. In a heterogeneous assay, e.g., the GST-NHP fusion protein can be anchored to glutathione-agarose beads. The interactive binding partner can then be added in the presence or absence of the test compound in a manner that allows interaction and binding to occur. At the end of the reaction period, unbound material can be washed away, and the labeled monoclonal antibody can be added to the system and allowed to bind to the complexed components. The interaction between a NHP moiety and the interactive binding partner can be detected by measuring the amount of radioactivity that remains associated with the glutathione-agarose beads. A successful inhibition of the interaction by the test compound will result in a decrease in measured radioactivity.

Alternatively, the GST-NHP moiety fusion protein and the interactive binding partner can be mixed together in liquid in the absence of the solid glutathione-agarose beads. The test compound can be added either during or after the species are allowed to interact. This mixture can then be added to the glutathione-agarose beads and unbound material is washed away. Again the extent of inhibition of the NHP moiety/binding partner interaction

can be detected by adding the labeled antibody and measuring the radioactivity associated with the beads.

In another embodiment of the invention, these same techniques can be employed using peptide fragments that correspond to the 5 binding domains of a NHP moiety and/or the interactive or binding partner (in cases where the binding partner is a protein), in place of one or both of the full length proteins. Any number of methods routinely practiced in the art can be used to identify and isolate the binding sites. These methods include, but are not 10 limited to, mutagenesis of the gene encoding one of the proteins and screening for disruption of binding in a co-immunoprecipitation assay. Compensatory mutations in the gene encoding the second species in the complex can then be selected. Sequence analysis of the genes encoding the respective proteins 15 will reveal the mutations that correspond to the region of the protein involved in interactive binding. Alternatively, one protein can be anchored to a solid surface using methods described above, and allowed to interact with and bind to its labeled binding partner, which has been treated with a proteolytic enzyme, 20 such as trypsin. After washing, a relatively short, labeled peptide comprising the binding domain may remain associated with the solid material, which can be isolated and identified by amino acid sequencing. Also, once the gene coding for the intracellular binding partner is obtained, short gene segments can be engineered 25 to express peptide fragments of the protein, which can then be tested for binding activity and purified or synthesized.

For example, and not by way of limitation, a NHP moiety can be anchored to a solid material as described, above, by making a GST-NHP moiety fusion protein and allowing it to bind to 30 glutathione agarose beads. The interactive binding partner can be labeled with a radioactive isotope, such as  $^{35}\text{S}$ , and cleaved with a proteolytic enzyme such as trypsin. Cleavage products can then be added to the anchored GST-NHP moiety fusion protein and allowed to bind. After washing away unbound peptides, labeled bound 35 material, representing the intracellular binding partner binding domain, can be eluted, purified, and analyzed for amino acid sequence by well-known methods. Peptides so identified can be

produced synthetically or fused to appropriate facilitative proteins using recombinant DNA technology.

The present invention is not to be limited in scope by the specific embodiments described herein, which are intended as 5 single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing 10 description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims. All referenced, patents, and patent applications cited herein are hereby incorporated by referenced in their entirety.

CONFIDENTIAL

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising at least  
24 contiguous bases of nucleotide sequence first disclosed in the  
5 NHP gene described in SEQ ID NO: 1.

2. An isolated nucleic acid molecule comprising a  
nucleotide sequence that:

10 (a) encodes the amino acid sequence shown in SEQ ID  
NO: 2; and  
(b) hybridizes under stringent conditions to the  
nucleotide sequence of SEQ ID NO: 1 or the  
complement thereof.

15 3. An isolated nucleic acid molecule comprising a  
nucleotide sequence that encodes the amino acid sequence shown in  
SEQ ID NO: 4.

20 4. An isolated nucleic acid molecule comprising at  
least 24 contiguous bases of nucleotide sequence first disclosed  
in the NHP gene described in SEQ ID NO: 6.

25 5. An isolated nucleic acid molecule comprising a  
nucleotide sequence that:

(a) encodes the amino acid sequence shown in SEQ ID  
NO: 7; and  
(b) hybridizes under stringent conditions to the  
nucleotide sequence of SEQ ID NO: 6 or the  
complement thereof.

30 6. An isolated nucleic acid molecule comprising a  
nucleotide sequence that encodes the amino acid sequence shown in  
SEQ ID NO: 7.

**ABSTRACT**

Novel human amino acid sequences are reported and nucleotide  
5 sequences encoding the same.

5000 4000 3000 2000 1000

SEQUENCE LISTING

<110> Turner, C. Alexander Jr.  
Donoho, Gregory  
Nehls, Michael  
Hilbun, Erin  
Zambrowicz, Brian  
Sands, Arthur T.

<120> Novel Human Proteins and Polynucleotides  
Encoding the Same

<130> LEX-0070-USA

<150> US 60/160,106  
<151> 1999-10-18

<150> US 60/162,547  
<151> 1999-10-29

<160> 7

<170> FastSEQ for Windows Version 4.0

<210> 1  
<211> 1356  
<212> DNA  
<213> homo sapiens

<400> 1

atggttcccg	aggtgagggt	cctctcctcc	ttgctggac	tcgcgcgtc	ctggttcccc	60
ctggactccc	acgctcgagc	ccgcccagac	atgttctgcc	ttttccatgg	gaagagatac	120
tccccccggcg	agagctggca	ccccctacttg	gagccacaag	gcctgatgta	ctgcctgcgc	180
tgtacacctgt	cagagggcgc	ccatgtgagt	tgttaccgccc	tccactgtcc	gcctgtccac	240
tgcgcgcgc	ctgtgacgga	gccacagcaa	tgctgtccca	agtgtgtgga	acctcacact	300
ccctctggac	tccggggcccc	accaaagtcc	tgccagcaca	acgggaccat	gtaccaacac	360
ggagagatct	tcagtgcaca	tgagctgttc	ccctccggcc	tgcccaacca	gtgtgtcctc	420
tgcagctgca	cagaggggcca	gatctactgc	ggcctcacaacaa	cctgccccga	accaggctgc	480
ccagcaccccc	tcccrcgtcc	agactcctgc	tgccargcct	gcaaagatga	ggcaagtgag	540
caatcgatg	aagaggacag	tgtgcagtgc	ctccatgggg	tgagacatcc	tcaggatcca	600
tgttccagtg	atgctgggag	aaagagaggc	ccgggcaccc	cagccccccac	tggcctcagc	660
gcccccctgt	gcttcatcccc	tcgcccacttc	agacccaagg	gagcaggcag	cacaactgtc	720
aagatcgtcc	tgaaggagaa	acataagaaa	gcctgtgtgc	atggcgggaa	gacgtactcc	780
cacggggagg	tgtggcaccc	ggccttcgt	gccttcggcc	ccttgcctgt	catcctatgc	840
acctgtgagg	atggccgcca	ggactgccag	cgtgtgaccc	gtcccccacga	gtacccctgc	900
cgtcaccccg	agaaaagtggc	tggaaagtgc	tgcaagattt	gcccagagga	caaagcagac	960
cctggccacca	gtgagatcag	ttcttaccagg	tgtcccaagg	caccgggccc	ggtcctcgtc	1020
cacacatcg	tatcccccaag	cccagacaac	ctgcgtcgct	ttgccttggaa	acacgaggcc	1080
tcggacttgg	tggagatcta	cctcttggaaag	ctggtraaag	atgagggaaac	tgaggctcag	1140
agaggtgaag	tacctggccc	aaggccacac	agccagaatc	ttccacttga	ctcagatcaa	1200
gaaagtcaagg	aagcaagact	tccagaaaaga	ggcacagcac	ttccgactgc	tcgctggccc	1260
ccacaaagg	cacttggaaac	tcttccttagc	ccagaccctg	gagctgaagg	tcacggccag	1320
tccagacaaa	gtgaccaaga	cataacaaag	acctaa			1356

<210> 2

<211> 451  
<212> PRT  
<213> homo sapiens

<400> 2

Met Val Pro Glu Val Arg Val Leu Ser Ser Leu Leu Gly Leu Ala Leu  
1 5 10 15  
Leu Trp Phe Pro Leu Asp Ser His Ala Arg Ala Arg Pro Asp Met Phe  
20 25 30  
Cys Leu Phe His Gly Lys Arg Tyr Ser Pro Gly Glu Ser Trp His Pro  
35 40 45  
Tyr Leu Glu Pro Gln Gly Leu Met Tyr Cys Leu Arg Cys Thr Cys Ser  
50 55 60  
Glu Gly Ala His Val Ser Cys Tyr Arg Leu His Cys Pro Pro Val His  
65 70 75 80  
Cys Pro Gln Pro Val Thr Glu Pro Gln Gln Cys Cys Pro Lys Cys Val  
85 90 95  
Glu Pro His Thr Pro Ser Gly Leu Arg Ala Pro Pro Lys Ser Cys Gln  
100 105 110  
His Asn Gly Thr Met Tyr Gln His Gly Glu Ile Phe Ser Ala His Glu  
115 120 125  
Leu Phe Pro Ser Arg Leu Pro Asn Gln Cys Val Leu Cys Ser Cys Thr  
130 135 140  
Glu Gly Gln Ile Tyr Cys Gly Leu Thr Thr Cys Pro Glu Pro Gly Cys  
145 150 155 160  
Pro Ala Pro Leu Pro Leu Pro Asp Ser Cys Cys Gln Ala Cys Lys Asp  
165 170 175  
Glu Ala Ser Glu Gln Ser Asp Glu Glu Asp Ser Val Gln Ser Leu His  
180 185 190  
Gly Val Arg His Pro Gln Asp Pro Cys Ser Ser Asp Ala Gly Arg Lys  
195 200 205  
Arg Gly Pro Gly Thr Pro Ala Pro Thr Gly Leu Ser Ala Pro Leu Ser  
210 215 220  
Phe Ile Pro Arg His Phe Arg Pro Lys Gly Ala Gly Ser Thr Thr Val  
225 230 235 240  
Lys Ile Val Leu Lys Glu Lys His Lys Lys Ala Cys Val His Gly Gly  
245 250 255  
Lys Thr Tyr Ser His Gly Glu Val Trp His Pro Ala Phe Arg Ala Phe  
260 265 270  
Gly Pro Leu Pro Cys Ile Leu Cys Thr Cys Glu Asp Gly Arg Gln Asp  
275 280 285  
Cys Gln Arg Val Thr Cys Pro Thr Glu Tyr Pro Cys Arg His Pro Glu  
290 295 300  
Lys Val Ala Gly Lys Cys Cys Lys Ile Cys Pro Glu Asp Lys Ala Asp  
305 310 315 320  
Pro Gly His Ser Glu Ile Ser Ser Thr Arg Cys Pro Lys Ala Pro Gly  
325 330 335  
Arg Val Leu Val His Thr Ser Val Ser Pro Ser Pro Asp Asn Leu Arg  
340 345 350  
Arg Phe Ala Leu Glu His Glu Ala Ser Asp Leu Val Glu Ile Tyr Leu  
355 360 365  
Trp Lys Leu Val Lys Asp Glu Glu Thr Glu Ala Gln Arg Gly Glu Val  
370 375 380  
Pro Gly Pro Arg Pro His Ser Gln Asn Leu Pro Leu Asp Ser Asp Gln  
385 390 395 400  
Glu Ser Gln Glu Ala Arg Leu Pro Glu Arg Gly Thr Ala Leu Pro Thr

405	410	415
Ala Arg Trp Pro Pro Arg Arg Ser Leu Glu Arg Leu Pro Ser Pro Asp		
420	425	430
Pro Gly Ala Glu Gly His Gly Gln Ser Arg Gln Ser Asp Gln Asp Ile		
435	440	445
Thr Lys Thr		
450		

<210> 3  
<211> 1290  
<212> DNA  
<213> homo sapiens

<400> 3		
atggttcccg aggtgagggt ccttcctcc ttgctggac tcgcgtgct ctggttcccc	60	
ctggactccc acgctcgagc ccgcaggac atgttctgcc tttccatgg gaagagatac	120	
tcccccggcg agagctggca cccctacttg gagccacaag gcctgtatgtatgc	180	
tgtacctgct cagagggcgc ccatgtgagt tggttaccgccc tccactgtcc gcctgtccac	240	
tgcccccagc ctgtgacgga gccacagcaa tgctgtccca agtgtgtgga acctcacact	300	
ccctctggac tccggggcccc accaaagtcc tgccagcaca acgggaccat gtaccaacac	360	
ggagagatct tcagtgccta tgagctgttc ccctcccgcc tgcccaacca gtgtgtcctc	420	
tgcagctgca cagagggcca gatctactgc ggcctcacaac cctgccccga accaggctgc	480	
ccagcacccc tcccrtctgc agactcctgc tgccargcct gcaaagatga gcacgtgag	540	
caatcgatg aagaggacag tgcgtacgtcg ctccatgggg tgagacatcc tcaggatcca	600	
tgtccagtg atgctggag aaagagaggc cggggcaccc cagccccac tggcctcagc	660	
gcccctctga gcttcatccc tcgcacttc agaccaagg gagcaggcag cacaactgtc	720	
aagatcgatc tgaaggagaa acataagaaa gcctgtgtgc atgggggaa gacgtactcc	780	
cacggggagg tggcacttccgt gccttcggcc cttgccttg catcctatgc	840	
acctgtgagg atggccgcca ggactgcccag cgtgtgaccc gttccaccga gtacccctgc	900	
cgtcaccccg agaaagtggc tggaaagtgc tgcaagatcc gcccagagga caaacgcac	960	
cctggccaca gtgagatccatccatccagg tgcgttccagg caccggggccg ggtcctcg	1020	
cacacatccgg tatccccaaag cccagacaac ctgcgtcgct ttgccttggaa acacgaggcc	1080	
tcggacttgg tggagatcta cctctggaaag ctggtraaag gaatcttcca cttgactcg	1140	
atcaagaaag tcaggaagca agacttccag aaagaggcac agcacttccg actgctcg	1200	
ggcccccacg aaggtcactg gaacgtcttc ctggcaga ccctggagct gaaggtc	1260	
gccagtccag acaaagtgc acagacataaa	1290	

<210> 4  
<211> 429  
<212> PRT  
<213> homo sapiens

<400> 4		
Met Val Pro Glu Val Arg Val Leu Ser Ser Leu Leu Gly Leu Ala Leu		
1 5 10 15		
Leu Trp Phe Pro Leu Asp Ser His Ala Arg Ala Arg Pro Asp Met Phe		
20 25 30		
Cys Leu Phe His Gly Lys Arg Tyr Ser Pro Gly Glu Ser Trp His Pro		
35 40 45		
Tyr Leu Glu Pro Gln Gly Leu Met Tyr Cys Leu Arg Cys Thr Cys Ser		
50 55 60		
Glu Gly Ala His Val Ser Cys Tyr Arg Leu His Cys Pro Pro Val His		
65 70 75 80		
Cys Pro Gln Pro Val Thr Glu Pro Gln Gln Cys Cys Pro Lys Cys Val		
85 90 95		
Glu Pro His Thr Pro Ser Gly Leu Arg Ala Pro Pro Lys Ser Cys Gln		

100	105	110	
His Asn Gly Thr Met Tyr Gln His Gly Glu Ile Phe Ser Ala His Glu			
115	120	125	
Leu Phe Pro Ser Arg Leu Pro Asn Gln Cys Val Leu Cys Ser Cys Thr			
130	135	140	
Glu Gly Gln Ile Tyr Cys Gly Leu Thr Thr Cys Pro Glu Pro Gly Cys			
145	150	155	160
Pro Ala Pro Leu Pro Leu Pro Asp Ser Cys Cys Gln Ala Cys Lys Asp			
165	170	175	
Glu Ala Ser Glu Gln Ser Asp Glu Glu Asp Ser Val Gln Ser Leu His			
180	185	190	
Gly Val Arg His Pro Gln Asp Pro Cys Ser Ser Asp Ala Gly Arg Lys			
195	200	205	
Arg Gly Pro Gly Thr Pro Ala Pro Thr Gly Leu Ser Ala Pro Leu Ser			
210	215	220	
Phe Ile Pro Arg His Phe Arg Pro Lys Gly Ala Gly Ser Thr Thr Val			
225	230	235	240
Lys Ile Val Leu Lys Glu Lys His Lys Lys Ala Cys Val His Gly Gly			
245	250	255	
Lys Thr Tyr Ser His Gly Glu Val Trp His Pro Ala Phe Arg Ala Phe			
260	265	270	
Gly Pro Leu Pro Cys Ile Leu Cys Thr Cys Glu Asp Gly Arg Gln Asp			
275	280	285	
Cys Gln Arg Val Thr Cys Pro Thr Glu Tyr Pro Cys Arg His Pro Glu			
290	295	300	
Lys Val Ala Gly Lys Cys Cys Lys Ile Cys Pro Glu Asp Lys Ala Asp			
305	310	315	320
Pro Gly His Ser Glu Ile Ser Ser Thr Arg Cys Pro Lys Ala Pro Gly			
325	330	335	
Arg Val Leu Val His Thr Ser Val Ser Pro Ser Pro Asp Asn Leu Arg			
340	345	350	
Arg Phe Ala Leu Glu His Glu Ala Ser Asp Leu Val Glu Ile Tyr Leu			
355	360	365	
Trp Lys Leu Val Lys Gly Ile Phe His Leu Thr Gln Ile Lys Lys Val			
370	375	380	
Arg Lys Gln Asp Phe Gln Lys Glu Ala Gln His Phe Arg Leu Leu Ala			
385	390	395	400
Gly Pro His Glu Gly His Trp Asn Val Phe Leu Ala Gln Thr Leu Glu			
405	410	415	
Leu Lys Val Thr Ala Ser Pro Asp Lys Val Thr Lys Thr			
420	425		

<210> 5

<211> 1792

<212> DNA

<213> homo sapiens

<400> 5

gccttggccg gcgctgcgcg ctcggcagac gcccgtcctc tccctgcttt ctcctccctct	60
ccctctcacc ttcccccttt ctttgatcgc ctctcccttc tgctggaccc ttcttcgtct	120
ctccatctct ccctcctttc cccgcgttct ctttccaccc ttctcttctt cccacccctag	180
acctcccttc ctgcctccct ttcctgccc ccgcgtcttc ctggcccttc tccgacccccc	240
ctcttagcagc agacctcctg gggctgtgg gttgatctgt ggccctgtgc cttccgtgtc	300
cttttcgtct cccttcctcc cgactccgct cccggaccag cggcctgacc ctggggaaag	360
gatggttccc gaggtgaggg tcctctctc cttgctggga ctgcgcgtgc tctggttccc	420
cctggactcc cacgctcgag cccgccccaga catgttctgc cttttccatg ggaagagata	480

ctccccccggc gagagctggc acccctactt ggagccacaa ggcctgatgt actgcctgcg	540
ctgtacctgc tcagaggcg cccatgttag ttgttaccgc ctccactgtc cgcctgtcca	600
ctgccccccag cctgtacgg agccacagca atgctgtccc aagtgtgtgg aacctcacac	660
tccctctgga ctccggggcc caccaaagtc ctgcccagcac aacgggacca tgtaccaaca	720
cgagagatc ttcaagtggcc atgagcttt cccctcccgctgccc aaccaggctg	780
ctgcagctgc acagagggcc agatctactg cggcctcaca acctgccccg aaccaggctg	840
cccagcaccc ctcccgctgc cagactcctg ctgccaagcc tgcaaagatg aggcaagtga	900
gcaatcgat gaagaggaca gtgtcagtc gctccatggg gtgagacatc ctcaggatcc	960
atgttccagt gatgctgggaa gaaagagagg cccgggcacc ccagccccca ctggcctcag	1020
cgccccctctg agcttcatcc ctcgcccattt cagacccaag ggagcaggca gcacaactgt	1080
caagatcgtc ctgaaggaga aacataagaa agcctgtgtg catggcggga agacgtactc	1140
ccacggggag gtgtggcacc cggccttcggc tgccctcggc cccttgcctt gcattcctatg	1200
cacctgttag gatggccccc aggactgcca gcgtgtgacc tgcgttgcggc agtaccctgt	1260
ccgtcaccccc gagaaaagtgg ctggaaagtgt ctgcaagatt tgcccaagagg acaaaggcaga	1320
ccctggccac agtgagatca gtttaccag gtgtcccaag gcaccgggccc gggtcctcg	1380
ccacacatcg gtatccccaa gcccagacaa cctgcgtcgc tttgccttgg aacacgaggc	1440
ctcggacttg gtggagatct acctctggaa gctggtaaaa gatgaggaaa ctgaggctca	1500
gagaggtgaa gtacctggcc caaggccaca cagccagaat cttccacttgc actcagatca	1560
agaaaagttag gaagcaagac ttccagaaag aggacacagca cttccgactg ctgcgtggcc	1620
cccacgaagg tcactggaaac gtcttccatggcc cccagaccct ggagctgaag gtcacggcca	1680
gtccagacaa agtgaccaag acataacaaa gacctaacag ttgcagatata gatgtgtata	1740
attgttgttataatataataa agttgcatttta ccctcaaaaaa aa	1792

<210> 6  
<211> 918  
<212> DNA  
<213> Homo sapiens

<400> 6

atgagcctct tcgggcttct cctgctgaca tctgcctgg ccggccagag acaggggact	60
caggcggaaat ccaaccttag tagtaaattt cagttttcca gcaacaagga acagaacggaa	120
gtacaagatc ctcagcatga gagaattttt actgtgtctt ctaatggaaat tatttcacagc	180
ccaaaggtttc ctcataacttta tccaaagaaat acggcttggc tatggagattt agtagcagta	240
gaggaaaatg tatggatata acttacgtttt gatgaaaatg ttggcttgc agacccagaa	300
gatgacatata gcaagtatga ttttttagaa gttgaggaac ccagtgtatgg aactatattttt	360
gggcgcgtgtt gtggcttctgg tactgtacca ggaaaacaga tttctaaagg aatcaaattt	420
aggataagat ttgtatctga tgaatattttt ctttctgaac cagggttctg catccactac	480
aacattgtca tgccacaattt cacagaagct gtgagtccctt cagtgctacc cccttcagct	540
ttggccacttgg acctgcttaa taatgttata actgccttta gtaccttggaa agaccttattt	600
cgatatacttgc aaccagagag atggcagttt gactttagaaat atctatatacg gccaacttgg	660
caacttcttgc gcaaggctttt tggttttggaa agaaaatcca gaggagataaa ttatgaaaatgg	720
gaaaaaaaaatc tgaagaccaa cttttacaaa tatttggcag agggaaaactt ctttaatattt	780
attatagtttta agctatttcaaa aaagtatctt ttggatattt atctttctt cttttttttcc	840
tttttcttctt tatttgcctt ccccccccaa aagtactata caatgtttca agaatgtatg	900
acatatgact taacttaa	918

<210> 7  
<211> 305  
<212> PRT  
<213> Homo sapiens

<400> 7

Met Ser Leu Phe Gly Leu Leu Leu Leu Thr Ser Ala Leu Ala Gly Gln			
1	5	10	15
Arg Gln Gly Thr Gln Ala Glu Ser Asn Leu Ser Ser Lys Phe Gln Phe			

20	25	30	
Ser Ser Asn Lys Glu Gln Asn Gly Val Gln Asp Pro Gln His Glu Arg			
35	40	45	
Ile Ile Thr Val Ser Thr Asn Gly Ser Ile His Ser Pro Arg Phe Pro			
50	55	60	
His Thr Tyr Pro Arg Asn Thr Val Leu Val Trp Arg Leu Val Ala Val			
65	70	75	80
Glu Glu Asn Val Trp Ile Gln Leu Thr Phe Asp Glu Arg Phe Gly Leu			
85	90	95	
Glu Asp Pro Glu Asp Asp Ile Cys Lys Tyr Asp Phe Val Glu Val Glu			
100	105	110	
Glu Pro Ser Asp Gly Thr Ile Leu Gly Arg Trp Cys Gly Ser Gly Thr			
115	120	125	
Val Pro Gly Lys Gln Ile Ser Lys Gly Asn Gln Ile Arg Ile Arg Phe			
130	135	140	
Val Ser Asp Glu Tyr Phe Pro Ser Glu Pro Gly Phe Cys Ile His Tyr			
145	150	155	160
Asn Ile Val Met Pro Gln Phe Thr Glu Ala Val Ser Pro Ser Val Leu			
165	170	175	
Pro Pro Ser Ala Leu Pro Leu Asp Leu Leu Asn Asn Ala Ile Thr Ala			
180	185	190	
Phe Ser Thr Leu Glu Asp Leu Ile Arg Tyr Leu Glu Pro Glu Arg Trp			
195	200	205	
Gln Leu Asp Leu Glu Asp Leu Tyr Arg Pro Thr Trp Gln Leu Leu Gly			
210	215	220	
Lys Ala Phe Val Phe Gly Arg Lys Ser Arg Gly Asp Asn Tyr Glu Lys			
225	230	235	240
Glu Lys Asn Leu Lys Thr Asn Phe Tyr Lys Tyr Leu Ala Glu Gly Asn			
245	250	255	
Phe Phe Asn Ile Ile Ile Val Lys Leu Phe Lys Lys Tyr Pro Leu Val			
260	265	270	
His Tyr Leu Ser Phe Phe Ser Phe Phe Ser Leu Phe Ala Phe Pro			
275	280	285	
Pro Gln Lys Tyr Tyr Thr Met Phe Gln Glu Cys Met Thr Tyr Asp Leu			
290	295	300	
Thr			
305			

**PATENT APPLICATION****DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION****ATTORNEY DOCKET NO. LEX-0070-USA**

As a below named inventor, I hereby declare that:

My residence/post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Novel Human Proteins and Polynucleotides Encoding the Same

the specification of which is attached hereto unless the following box is checked:

was filed on \_\_\_\_\_ as US Application Serial No. or PCT International Application Number \_\_\_\_\_ and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above. I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR 1.56.

**Foreign Application(s) and/or Claim of Foreign Priority**

I hereby claim foreign priority benefits under Title 35, United States Code Section 119 of any foreign application(s) for patent or inventor(s) certificate listed below and have also identified below any foreign application for patent or inventor(s) certificate having a filing date before that of the application on which priority is claimed:

COUNTRY	APPLICATION NUMBER	DATE FILED	PRIORITY CLAIMED UNDER 35 U.S.C. 119
			YES: <u>      </u> NO: <u>      </u>
			YES: <u>      </u> NO: <u>      </u>

**Provisional Application**

I hereby claim the benefit under Title 35, United States Code Section 119(e) of any United States provisional application(s) listed below:

APPLICATION SERIAL NUMBER	FILING DATE
60/160,106	10/18/1999
60/162,547	10/29/1999

**U.S. Priority Claim**

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Section 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NUMBER	FILING DATE	STATUS(patented/pending/abandoned)

**POWER OF ATTORNEY:**

As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) listed below to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

**Lance K. Ishimoto, Reg. No. 41866****Send Correspondence to:**

Lance K. Ishimoto  
Lexicon Genetics Incorporated  
4000 Research Forest Drive  
The Woodlands, TX 77381

**Direct Telephone Calls To:**

Lance K. Ishimoto  
(281) 362-6554

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

**DECLARATION AND POWER OF ATTORNEY  
FOR PATENT APPLICATION (continued)**

**ATTORNEY DOCKET NO. LEX-0070-USA**

Full Name of Inventor: C. Alexander Turner, Jr.

Citizenship: USA

Residence: 67 Winter Wheat Place, The Woodlands, TX 77381

Post Office Address: Same

Inventor's Signature

Date

Full Name of Inventor: Gregory Donoho

Citizenship: USA

Residence: 41 Fallenstone Dr., The Woodlands, TX 77381

Post Office Address: Same

Inventor's Signature

Date

Full Name of Inventor: Michael C. Nehls

Citizenship: Germany

Residence: Paul-Keller-Strasse 6, Stockdorf, Germany 82131

Post Office Address: Same

Inventor's Signature

Date

Full Name of Inventor: Erin Hilbun

Citizenship: USA

Residence: 16222 Stuebner Airline, Spring, TX 77379

Post Office Address: Same

Inventor's Signature

Date

Full Name of Inventor: Brian Zambrowicz

Citizenship: USA

Residence: 18 Firethorne Place, The Woodlands, TX 77382

Post Office Address: Same

Inventor's Signature

Date

Full Name of Inventor: Arthur T. Sands

Citizenship: USA

Residence: 163 Bristol Bend Circle, The Woodlands, TX 77382

Post Office Address: Same

Inventor's Signature

Date